Education. Evidence. Regrowth.
Prioritize knowledge. Make better choices.
Sort good studies from the bad.
Get bigger hair gains.
PhD's, resarchers, & consumer advocates.
Founder, researcher, & consumer advocate
Our team of PhD’s, researchers, & more
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
I have attached my before and afters of my progress since joining this group...
I’m convinced I’ve recovered to probably the hairline I had 3 years ago. Super stoked…
My friends actually told me, “Your hairline improved. Your hair looks thicker...
I also feel my hair has a different texture to it now…
Firstly thank you for your work in this field. I am immensely grateful that...
I just wanted to thank you for all your research, for introducing me to this method...
To be honest I am having fun with all this and I still don’t know how much...
I see a massive amount of regrowth that is all less than about 8 cm long...
150+ member experiences.
Popular treatments. But do they work?
Top-selling ingredients, quantified.
The truth about hair loss "best sellers".
Xyon Health
Strut Health
Happy Head
DS Laboratories
Advanced Trichology
Fully Vital
Xyon Health
DrFormulas
Revivogen MD
Standardized rubrics to evaluate all treatments.
Is this treatment well studied?
How much regrowth can you expect?
Is this treatment safe & sustainable?
Apps, tools, guides, freebies, & more.
100+ free articles.
Our team’s peer-reviewed studies.
Education. Evidence. Regrowth.
PhD's, resarchers, & consumer advocates.
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
Read the experiences of members
Finasteride is a drug approved by the FDA to treat benign prostate hyperplasia and androgenic alopecia. It is prescribed as a 1 mg daily tablet for men with androgenic alopecia. It is also prescribed in higher dosages for women suffering from female pattern hair loss. This ranges from 1.0-5.0 mg daily.
Finasteride is available in different formulations. The best option is determined on a patient-by-patient basis.
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
There are two main finasteride formulations: oral and topical. Doctors typically prescribe oral finasteride, as it’s a time-tested formulation with a high success rate. Many telehealth providers have sprouted up in recent years, offering topical and oral versions of the drug. Topical finasteride has become increasingly popular as more studies confirm its efficacy and relative safety versus oral finasteride.
As concluded in one study:
Topical finasteride significantly improves hair count compared to placebo and is well tolerated. Its effect is similar to that of oral finasteride, but with markedly lower systemic exposure and less impact on serum DHT concentrations. [1]https://pubmed.ncbi.nlm.nih.gov/34634163/
Clinical studies have shown that oral and topical formulations improve hair parameters equivalently in target area hair counts.[2]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297965/ As such, many people looking to minimize their risk of side effects from finasteride often prefer the topical formulation, and they rationalize that decision by arguing that topical finasteride (1) is just as effective as oral finasteride, and (2) remains localized to the scalp, so it must not have any systemic effects elsewhere in the body.
In reality, both of these arguments are wrong.
A graph representing the daily dose exposure of topical finasteride (y-axis) versus the amount of serum DHT reductions in participants (x-axis). Across all studies referenced in the graph, topical finasteride led to hair parameter improvements.
As mentioned, finasteride is typically prescribed as a once-daily 1mg tablet. At 1mg daily, finasteride is sometimes branded as Propecia®. Using more than 1mg per day isn’t likely to improve results.[3]https://pubmed.ncbi.nlm.nih.gov/10495375/
However, it may increase the risk of side effects. Nearly all clinical studies use 1mg, as it’s the gold standard for treating male pattern baldness. 5 mg finasteride is typically used to treat men diagnosed with benign prostatic hyperplasia (under the label Proscar®).
Oral Propecia® (i.e., 1mg daily of finasteride) is prescribed under its brand name and as a generic formulation through many telehealth companies. Generic versions of the drug typically deliver similar results, and often at a fraction of the cost.
Finasteride topicals include gels, liquid solutions, and liquid sprays. Foams are available as well.
A previous post centered on the best topical finasteride dosage determined that finasteride has a highly-sensitive and dose-dependent response curve.
In other words, 0.01 mg of finasteride barely reduces any DHT, while 0.2 mg reduces almost as much DHT as 5 mg, a much larger dose.[4]https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738 1% topical formulations essentially guarantee systemic absorption.
Those aiming to avoid the side effects may want to consider a formula with lower percentages of the active drug.
It depends on two factors: (1) the presence of side effects, and (2) whether a patient has diffuse thinning or localized hair loss.
When weighing the pros and cons of finasteride formulas, doctors often have patients start with oral finasteride. This is because oral finasteride has the strongest clinical evidence for treating male pattern hair loss, and it provides some degree of protection across all balding-prone areas.
If side effects occur on oral finasteride at 1 mg daily, doctors may consider lowering the dose to 0.2 mg daily to see if this reduces side effects. If issues persist, other options can be explored – such as topical formulations.
Under these circumstances, users may introduce topical finasteride at a 1-2 mL daily of 0.025% to 0.3% finasteride. If side effects persist, it may be necessary to lower that dose all the way to 0.005% x 2 mL daily, and start tracking serum DHT levels to measure – as a proxy – how much finasteride is actually going systemic (as these levels vary greatly depending on the person and any adjuvant treatments that might be influencing topical absorption – i.e., retinoic acid, microneedling, etc.).
If someone wants to use topical finasteride, they should recognize that topical formulations of the drug are most appropriate for people who have localized hair loss (i.e., hair loss only at the temples and/or crown), rather than people with diffuse thinning (i.e., hair loss throughout the entire scalp).
This is because diffuse thinners have a larger area of the scalp to cover with a topical. That requires a higher amount of mL per application daily of topical finasteride to cover all zones. When holding constance the percentage dilution of topical finasteride, the more mL applied daily, the higher likelihood some of that additional finasteride will leak into the bloodstream and cause systemic effects – thereby defeating the whole effort of the topical in the first place.
For these reasons, diffuser thinners need to take extra care to titrate down their topical finasteride doses, or perhaps consider oral formulations of finasteride to maximize their scalp coverage and thereby improve their odds of long-term success.
For those who don’t experience any sexual side effects, long-term use of oral finasteride may be advisable, given its success rate. And for those who experience adverse systemic effects of oral finasteride, or those wary about potential issues with the oral formulation, topical finasteride may be the better option.
References[+]
Finasteride and dutasteride are drugs that lower the hormone dihydrotestosterone (DHT), which is a hormone that is causally linked to both benign prostatic hyperplasia and male pattern hair loss. While both drugs tend to be effective hair loss treatments for men, they do come with a risk of side effects –most commonly sexual side effects and the growth of male breast tissue (gynecomastia).
These side effects are believed to occur because of finasteride and dutasteride’s inhibitory effects on 5-alpha reductase – an enzyme that helps convert free testosterone into dihydrotestosterone. By inhibiting this enzyme, finasteride and dutasteride are able to therapeutically lower DHT levels to improve the symptoms of an enlarged prostate and/or regrow hair. However, the inhibition of 5-alpha reductase can come with undesired side effects in 5-15% of men using these drugs – mainly due to the hormonal shifts that occur throughout the body when 5-alpha reductase activity is suppressed.
Oral finasteride & minoxidil available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Based on clinical data (so far), there aren’t yet reliable blood tests to determine someone’s risk of sexual side effects from drugs like finasteride or dutasteride. Having said that, clinical studies show that men who have low levels of free testosterone and/or high levels of sex hormone binding globulin tend to be at the highest risk of “low libido”.[1]https://pubmed.ncbi.nlm.nih.gov/25800960/
As such, some clinicians have argued (anecdotally) that patients reporting side effects from finasteride and dutasteride tend to already have hormonal imbalances associated with reduced libido prior to starting the drug. As such, these same clinicians sometimes suggest that by taking measures to (1) improve free testosterone, and/or (2) reduce sex hormone binding globulin – these men tend to see improvements to libido and, as a consequence, sport a higher tolerability for drugs like finasteride and dutasteride.
So, if you’re worried about sexual side effects from finasteride and dutasteride, there is at least some anecdotal and observational evidence suggesting that testing free testosterone and sex hormone binding globulin might help to predict your actual risk tolerance. With that said, it’s important to note that the data here remains limited.
Gynecomastia is the growth of male breast tissue. It results from prolonged, elevated levels of the hormones prolactin and/or estrogen.
When it comes to the use of finasteride and dutasteride, blood tests can likely be used to determine someone’s risk of gynecomastia from both drugs.
Gynecomastia is estimated to affect between 0.25% to 1% of healthy people using 5-alpha reductase inhibitors, with 5-year retrospective studies in men with benign prostate hyperplasia suggesting an incidence of up to 3% to 5%. [2]https://pubmed.ncbi.nlm.nih.gov/23067029/
Interestingly, those who start finasteride and/or dutasteride while already having elevated levels of prolactin and estrogen might be at a higher risk of developing gynecomastia. This is because drugs like finasteride and dutasteride can raise blood levels of both testosterone and/or estrogen by 10-20%, depending on the dose.[3]https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf[4]https://journals.sagepub.com/doi/abs/10.1177/2051415820926301 Consequently, as blood levels of estrogen and/or prolactin rise, these hormones can stimulate the growth of ductal tissue and alveolar differentiation – both of which relate to the growth of male breast tissue.[5]https://www.ncbi.nlm.nih.gov/books/NBK279105/
Hormones affecting growth and differentiation of breast tissue. Adapted from “Gynecomastia: Etiology, Diagnosis, and Treatment” (2019)[6]https://www.ncbi.nlm.nih.gov/books/NBK279105/
So, for those starting the drug with borderline-high estrogen, the additional lift in estrogen levels may put someone in the “danger zone” for gynecomastia.
For peace of mind, people can always order blood tests for prolactin and estrogen prior to starting finasteride or dutasteride. Additional tests can be performed further down the line.
If levels are within range, the risk of gynecomastia is likely much lower. This can be done with a primary care physician. Those based in the U.S. (and other countries that offer direct-to-consumer lab testing), can order tests through the links below.
Not a member? Sign up today to become part of the Perfect Hair Membership Community. You’ll gain instant access to a customized hair regrowth plan, 50+ guides, 30+ product reviews, 60+ case studies, community support forums, expert interviews, and more.
While it’s up for debate if blood tests can actually predict someone’s risk of sexual side effects from finasteride or dutasteride, there is evidence that estrogen and prolactin levels pre-hair loss drugs might give some insights into the risk of developing gynecomastia. The totality of evidence suggests that finasteride and dutasteride may raise estrogen levels by 10-20%. Therefore, if your pre-finasteride levels of estrogen and/or prolactin are within 10-20% of the upper limit, it’s probably best to find ways to lower these levels before committing to the drug.
Diet, lifestyle, and environmental changes are often enough to normalize these hormones in many men.
The best predictor of hair regrowth from finasteride comes not from a blood test, but from an accurate hair loss diagnosis. After all, two-year clinical studies show that in otherwise healthy men with androgenic alopecia that presents in its standard horseshoe pattern, response rates for finasteride tend to hover around 80-90%.[9]https://www.sciencedirect.com/science/article/pii/S0022202X15529357
Recently, marketers have begun pushing genetic testing to determine someone’s response rate to finasteride and dutasteride. Preliminary data from poorly designed clinical studies suggests that perhaps there are some genes associated with higher-magnitude responses from both drugs, and also a better success rate. For instance, one study suggested that genetic “CAG repeat score” might help determine the response rate to finasteride, and that this data could be collected through blood draws.[10]https://pubmed.ncbi.nlm.nih.gov/31949455/
But again, the evidence here is limited and preliminary. Given the overwhelmingly high odds of a response to finasteride overall, we tend to place more weight on an accurate diagnosis than on genetic testings for either drug.
References[+]
↑1 | https://pubmed.ncbi.nlm.nih.gov/25800960/ |
---|---|
↑2 | https://pubmed.ncbi.nlm.nih.gov/23067029/ |
↑3 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf |
↑4 | https://journals.sagepub.com/doi/abs/10.1177/2051415820926301 |
↑5, ↑6 | https://www.ncbi.nlm.nih.gov/books/NBK279105/ |
↑7 | truehealthlabs.com/product/prolactin |
↑8 | truehealthlabs.com/product/estradiol-e2 |
↑9 | https://www.sciencedirect.com/science/article/pii/S0022202X15529357 |
↑10 | https://pubmed.ncbi.nlm.nih.gov/31949455/ |
Finasteride is the most powerful, well-studied, FDA-approved drug for androgenic alopecia (AGA). It stops AGA progression in 80-90% of men and, on average, leads to a 10% increase in hair count over two years. For men wanting a hands-off approach to hair maintenance, finasteride is often an excellent option.
That said, finasteride isn’t for everyone. While its risk of side effects are often overstated online, the drug appears to reduce libido in a certain percentage of men and may induce gynecomastia. The drug can also temporarily lower sperm counts, which might make conception more difficult during its first six months of use. In some men, the use of finasteride appears to increase anxiety and/or depression.
The true incidence and magnitude of these reports are hard to discern. Depending on the study we cite and the questionnaire design, these effects can range from 1% to 40%. Whether or not one should worry about finasteride side effects may depend on their current hormonal profile and mental health. Keep reading to learn more.
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Gynecomastia is the growth of male breast tissue. It results from elevated hormones such as prolactin and estrogen. While gynecomastia is estimated to only affect between 0.25-1.00% of people on 5-alpha reductase inhibitors (such as finasteride), those who start the drug with already elevated levels of prolactin and estrogen are likely at a higher risk of its development.
Drugs like finasteride can raise blood levels of both testosterone and estrogen by 10-30%, depending on the dose. So, for those starting the drug with borderline-high estrogen, the additional lift in estrogen levels may put someone at greater risk of gynecomastia.
Because it lowers DHT levels (a hormone that helps maintain male sex characteristics), some studies have shown that a percentage of finasteride users report sexual side effects ranging from decreased sex drive to reduced semen volume to erectile dysfunction. Studies vary widely, but incidents could be as low as 1-2% of users.
Female users should be aware that Finasteride can potentially mutate and/or inhibit the development of male fetus genitalia.[1]dailymed.nlm.nih.gov/dailymed/lookup.cfm As such, pregnant women are neither prescribed finasteride nor advised to even handle the medication.
On hair loss forums, some men taking finasteride have complained of changes to cognition, specifically, a feeling of brain fog since starting therapy. To date, this hasn’t been reported to significant degrees in clinical studies. This may be because even if the effects do exist, it’s likely a subtle, gradual side effect that many may not attribute to the drug.
Animal models have demonstrated that finasteride can indeed change brain chemistry, especially after transitioning off of the drug. But it’s important to note that animals in those studies take dosages of finasteride thousands of times greater than what is prescribed to humans.
In any case, it’s not unreasonable that those with depression, anxiety, and/or bipolar disorder should proceed with caution and speak with their doctor to closely monitor the effects of finasteride use.
Regardless of the specific side effect that’s being targeted to reduce, the strategies are all similar: find ways to (1) reduce daily drug exposure, (2) localize the drug’s effects to the scalp, and (3) do lab tests to determine personal risk for certain side effects like gynecomastia. These strategies are outlined in detail below:
As a hair loss drug, finasteride is typically prescribed orally at 1mg daily. Having said that, there’s evidence that 0.2mg daily is nearly just as effective at improving hair counts while simultaneously reducing total drug exposure by 80%. For many people, this coincides with a reduction in perceived side effects.
Finasteride’s dose-dependent, logarithmic response curve on serum DHT reduction
If side effects, or anticipatory anxiety, are a concern, try lowering the dose of the drug from 1mg daily to 0.2mg daily. After all, small clinical studies have demonstrated that doses as low as 0.2mg daily still improve hair counts, and may also confer a slightly smaller magnitude and/or severity of side effects (at least anecdotally).[2]https://pubmed.ncbi.nlm.nih.gov/10495375/
Unfortunately, finasteride is a hair loss drug that must be continued indefinitely for its effectiveness to remain. When finasteride treatment is stopped, men typically lose what hair regrowth they gained within 3-12 months. For these reasons, it’s not advised to drop below doses equating to 0.2mg daily – as efficacy may rapidly diminish below this threshold.
If finasteride side effects don’t go away with reduced usage, most users report any lingering side effects go away after discontinuing the drug within 2-3 weeks, and for some, up to a few months. If problems persist beyond that, it’s important to contact your prescribing physician.
There are two primary ways to localize finasteride’s effects to the scalp. These methods minimize the amount of the drug that circulates throughout the bloodstream, thus minimizing the side effects of finasteride. Both entail switching from an oral to topical formula.
Studies show that – when formulated properly – topical finasteride may reduce the risk of side effects by 30-90%. One 16-month study on 0.005% topical finasteride demonstrated significant hair improvements, no drug-associated side effects, and no impact on blood hormonal levels.[3]https://dx.doi.org/10.3109%2F09546639709160517 This suggests that any absorption of the drug beyond the scalp was metabolized quickly enough to not impact serum DHT levels.
Other studies have demonstrated that higher doses of topical finasteride also confer benefit, and at smaller reductions of serum DHT (i.e., a proxy for systemic absorption) and perhaps side effects, too.[4]https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.17738 Having said that, if minimizing side effects are a top priority, we still recommend starting with the minimum viable dose of topical finasteride – 0.005% x 2 mL daily – and working your way up from there.
Also known as mesotherapy, intradermal delivery methods inject finasteride into the scalp. While there aren’t yet clinical studies of mesotherapy finasteride in reputable journals, there are clinical studies of mesotherapy dutasteride – a drug that is more powerful at reducing DHT levels versus finasteride and that also has a longer half-life (which makes it a better candidate for less-frequent injections into the scalp – since the drug will stay active for longer).
A small number of clinical studies suggest that scalp injections of ~0.01% x 1-2 mL of dutasteride, once every 1-3 months, do not appreciably alter serum hormones, nor do they result in any reported cognitive or sexual side effects. They do, however, lead to statistically significant hair improvements.
Determining personal risk ahead of time, and getting a baseline measure of hormonal health, can help people decide if finasteride is right for them. It can also help people keep track of how the drug is influencing their serum hormones.
There aren’t yet clinical studies demonstrating the predictability of finasteride side effects related to lowered libido or sexual dysfunction. There are, however, clinical studies suggesting men who are experiencing reduced libidos tend to also have low levels of free testosterone and/or high levels of sex hormone binding globulin.
For these reasons, some clinicians recommend getting these hormones tested prior to starting finasteride. While finasteride isn’t known to have a major influence over these hormones, borderline-abnormal tests may make someone more likely to report these problems, irrespective of whether they’re using hair loss drugs.
For peace of mind, blood tests for prolactin and estrogen can be ordered prior to starting finasteride. Clinical studies do show that finasteride and dutasteride can slightly increase levels of estrogen, and that a rise in estrogen and/or prolactin can be pathogenically linked to the development of gynecomastia, also known as male breast development.[5]https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf[6]https://journals.sagepub.com/doi/abs/10.1177/2051415820926301[7]https://www.ncbi.nlm.nih.gov/books/NBK279105/
If you’re worried about this side effect, test your estrogen and prolactin levels. If they’re within 10-20% of the upper limit for normal, then finasteride or dutasteride use may put you “over the edge” and into that risk category of gynecomastia. Under these circumstances, consider dietary, lifestyle, and/or environmental interventions to lower levels of these into a normal range prior to starting finasteride, and rechecking these hormones regularly or if breast tenderness begins to develop.
Also keep in mind that blood tests for hormones are just proxies for what might be occurring elsewhere in the body. Therefore, it’s entirely possible for serum blood tests to mislead us into thinking we have “normal” levels of hormones, when our tissue hormonal profiles might be out-of-range. The inverse is also true: out-of-range blood hormones don’t always signify out-of-range tissue hormones. So, treat any laboratory test as preliminary, and recognize the science supporting these tests – at least for their predictability of finasteride side effects – is still in its infancy.
Anyone interested in doing these lab tests can do so with the help of their primary care physician. Or, those based in the U.S. (or any other country that offers direct-to-consumer lab testing) may be able to order tests through the links below.
For more information, see these resources (no affiliate links):
Topical finasteride can still go systemic. Having said that, clinical studies also show that daily doses of topical finasteride as low as 0.005% x 2 mL can still produce positive hair parameter changes over 16 months, and without impacting serum DHT levels (a proxy for systemic circulation of the drug).
For those worried about the sexual side effects of finasteride, this formulation of topical finasteride might be most appropriate. However, if you go down this route, you also may want to consider periodically testing serum DHT levels – as members inside our membership community have found that even at these ultra-low dilutions of finasteride, serum DHT tests can still decline by more than 25%.
Changes to serum DHT levels can help people understand just how much topical finasteride (if any) is going systemic. In general, DHT fluctuations smaller than 20% are considered biologically insignificant.
Directions for how to do this can be found inside our comprehensive finasteride guides, available only to members.
So, consider these options (and the data) before giving up entirely on finasteride. There are many ways to leverage its power, mitigate its risks, and perhaps take your hair regrowth to a new level.
References[+]
↑1 | dailymed.nlm.nih.gov/dailymed/lookup.cfm |
---|---|
↑2 | https://pubmed.ncbi.nlm.nih.gov/10495375/ |
↑3 | https://dx.doi.org/10.3109%2F09546639709160517 |
↑4 | https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.17738 |
↑5 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf |
↑6 | https://journals.sagepub.com/doi/abs/10.1177/2051415820926301 |
↑7 | https://www.ncbi.nlm.nih.gov/books/NBK279105/ |
↑8 | truehealthlabs.com/product/prolactin |
↑9 | truehealthlabs.com/product/estradiol-e2 |
If experiencing side effects from minoxidil, it’s best to speak with the prescribing physician as soon as possible to discuss next steps. Discontinuing use, however, is not the only option. There are strategies to reduce minoxidil’s side effects (while still benefiting from the drug) in both topical and oral formulations. This article will focus on reducing adverse events from topical minoxidil, depending on the side effect you’re experiencing:
High-strength topical minoxidil available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
For the most part, side effects from minoxidil are minor. Here are a few adverse events reported in the clinical literature (and online), the percent of people they tend to affect, and strategies on how to go about reducing or resolving them.
Skin irritation, dandruff, and/or dermatitis are the most frequently reported side effect from minoxidil. These tend to be reported by 2-7% of topical minoxidil users.
One study demonstrated that 80% of these reports were not actually due to minoxidil, but the carrier ingredient used to help minoxidil penetrate into the dermis: propylene glycol.[1]thaiscience.info/…ticle/JMAT/10986429.pdf
In these cases, simply switching to a minoxidil product without propylene glycol solved most reports of skin irritation. As such, if you’re experiencing these problems, you may want to experiment with switching minoxidil brands or formulations — specifically to a product that does not contain propylene glycol. Examples include:
If skin irritation persists on these new formulations, consider titrating the dose of topical minoxidil. You can achieve this by moving from twice-daily 5% minoxidil to once-daily 5% minoxidil. If that doesn’t work, try moving from once-daily 5% minoxidil to once-daily 2% minoxidil. If that doesn’t work, consider trying oral minoxidil at doses from 0.25mg to 5.0mg (more on this below).
Not a member? Join the Perfect Hair Health Membership Community to build your customized regrowth roadmap and receive personalized minoxidil recommendations.
Some topical minoxidil users have reported under-eye bags and/or signs of accelerated skin aging. However, these reports are not reflected in the clinical literature; they’re anecdotal. Even still, while there’s currently no evidence (to which we’re aware) that minoxidil accelerates aging, there is a mechanistic argument to be made that topical minoxidil might increase the perception of skin aging and/or under-eye bags. This is likely due to two factors:
If these side effects reflect your own experiences with topical minoxidil, consider the following:
In most cases, these changes make enough of an impact to reduce, mitigate, or even eliminate these side effects altogether.
In rarer cases, topical minoxidil results in heart palpitations or headaches. In some cases, these side effects are related to the formulation of minoxidil; in others, they’re due to the drug itself. If you don’t intend on quitting the drug outright after having experienced these effects, it’s critical to tease out which category you fall into — and to approach troubleshooting very carefully.
If you’re experiencing a headache after topical minoxidil applications, the first question to ask is: is it the minoxidil itself, or an ingredient applied alongside the minoxidil that’s causing this experience?
In many cases, the scent of topical minoxidil is what’s causing someone’s headache after applying the drug topically. This can be due to a scent added to the formulation, or even the off-gassing of the alcohol (if you’re using a topical that contains ethanol or an alcohol as a carrier ingredient).
Under these circumstances, simply switching topical minoxidil brands to something that is (1) unscented, and (2) does not contain alcohol should be enough to resolve symptoms. If this doesn’t work, it’s likely that the headaches are a direct result of the minoxidil itself.
If this is the case, consider titrating the dose of minoxidil from twice-daily 5% minoxidil to once-daily 5% minoxidil. If that doesn’t work, consider trying nanoxidil — a minoxidil analogue that has a lower molecular weight and may confer a slightly better safety profile (at least according to very biased research from the company selling nanoxidil, DS Laboratories). Anecdotally, members of our community who have made this switch have mostly reported resolution of headaches secondary to topical minoxidil after switching to topical nanoxidil. So it’s not a bad idea.
If that doesn’t work, minoxidil may not be the right medication for you — at least when it comes to fighting hair loss. The good news is there are many other options.
If you’ve noticed that, after applying topical minoxidil, your heart feels as though it “skips a beat” or begins beating irregularly, these signs are indication of a drug sensitivity to minoxidil itself. These effects are rare, but they likely impact up to 1% of people who have tried topical minoxidil.
If this is your experience, please speak to a medical professional and strongly consider discontinuing the medication. We do know of people who’ve managed these side effects by titrating the dose of topical minoxidil from twice-daily 5% to once-daily 5%, and even lower. Having said that, it’s critical to remember that our heart is more important than our hair. There are many other treatment options aside from topical minoxidil for your hair loss, and if you’re getting heart palpitations after applying the medication, it’s probably best to start exploring those rather than manage a medication that — despite being FDA-approved — still has lower qualities of evidence supporting its long-term use.
References[+]
↑1 | thaiscience.info/…ticle/JMAT/10986429.pdf |
---|
Finasteride is one of the most commonly-prescribed medications for treatment of male pattern hair loss—also known as androgenic alopecia (AGA). But it’s also used as an off-label treatment for female pattern hair loss. Evidence suggests this medication can help regrow hair in both sexes.
But what’s the best dose of finasteride for women with AGA? Unfortunately, it’s complicated. This article sets out to evaluate the data, uncover the answers, and provide recommendations based on the current landscape of clinical research.
Oral finasteride & minoxidil available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Finasteride is a drug developed to inhibit type II 5-alpha reductase. This is an enzyme in the body that converts free testosterone in dihydrotesterone (DHT).
Essentially, finasteride lowers DHT levels by reducing the amount of type II 5-alpha reductase circulating throughout our bodies. And by taking finasteride at 0.2 to 5.0 mg daily dosages, we can often reduce total DHT levels by 70%. [1]https://www.ncbi.nlm.nih.gov/books/NBK513329/
DHT is not just a metabolite of testosterone; it’s also the primary male hormone causally associated with androgenic alopecia.
We know this because studies have shown that men who cannot produce DHT are nearly fully-protected from going bald throughout a lifetime. Furthermore, clinical studies on DHT-lowering drugs – such as finasteride – show that if DHT levels are suppressed enough, 80-90% of men can arrest the progression of their pattern hair loss and even regrow 10-20% of their lost hair. [2]https://pubmed.ncbi.nlm.nih.gov/29407002/ [3]https://www.ncbi.nlm.nih.gov/books/NBK430924/
Similarly, studies on females with androgenic alopecia have shown that finasteride can also improve their hair loss outcomes. The evidence is less robust than for men, but finasteride is something many women should consider trying in order to improve their pattern hair loss.
In men, the FDA has approved the use of 1mg of finasteride for pattern hair loss. However, male and female hair loss cases are not always the same. Reducing DHT levels is often of therapeutic interest to fighting AGA – and for both sexes – but some clinical evidence suggests that females might need a different dose of finasteride versus males.
Finasteride has what is known as a dose-dependent, logarithmic response curve for DHT reduction. In other words: a little bit of finasteride reduces nearly as much DHT as a lot of finasteride. For an example, see this chart:
Clinical studies have demonstrated that 0.2 mg and 5.0 mg reduce nearly the same amount of finasteride: 69% versus 72%, respectively.
Because of this, a lot of people actually prefer to use lower dosages of finasteride than what is generally prescribed. This practice is also supported by clinical data. For instance, in men, 0.2mg of finasteride AGA at a statistically similar level as 1.0 mg of finasteride over the course of a year. [4]https://europepmc.org/article/med/15319158
But is the same true with females? Unfortunately, the data is less clear.
The FDA approves the use of 1 mg of finasteride for male pattern hair loss.[5]https://www.fda.gov/drugs/information-drug-class/5-alpha-reductase-inhibitor-information But the underlying causes of male and female pattern hair loss cases (androgens such as DHT) are not always the same. Furthermore, while reducing DHT levels is of therapeutic relevance in treating AGA in men and women, some clinical evidence suggests that females might need a different dose of finasteride versus males.
What does the available research tell us? Here are a few of the key studies on finasteride for women, and their main findings (summarized in the table below).
Type of study | Number of patients | Patient condition | Finasteride dosage | Length of treatment | Assessment parameters | Outcomes | Reference |
Double-blind, randomized control trial | 67 treated, 70 placebo | AGA, post-menopausal, normal serum testosterone | 1 mg, daily | 12 months | Hair counts, photographic assessment, self-assessment, scalp biopsies | Serum DHT reduction but no effect on hair loss outcomes compared to placebo | [6]https://pubmed.ncbi.nlm.nih.gov/10674382/[7]https://pubmed.ncbi.nlm.nih.gov/11050579/ |
Randomized, unmasked trial | 12 finasteride, 12 flutamide, 12 cyproterone acetate with estradiol, 12 no treatment | 48 women, hyperandrogenic, age- and weight matched controls | 5 mg, daily | 12 months | Ludwig classification15 of female hair loss, self-assessment, and investigator assessment | No effect with finasteride | [8]https://pubmed.ncbi.nlm.nih.gov/11050579/ |
Single-blind, placebo-controlled trial | 24 female patients included | AGA, age 23-38 years (mean 33) | 1 ml topical application (0.005%), twice daily to affected area | 16 months | Semi-quantitative investigator assessment, hair shedding quantification, self-assessment | Hair count and hair density improvements versus placebo (data not sex-stratified) | [9]https://www.tandfonline.com/doi/abs/10.3109/09546639709160517 |
Small trial | 5 treated | Post-menopausal, normal androgen levels | 2.5 or 5 mg, daily | 18 months, review every 6 months | Self-assessment, investigator assessment, photographic assessment | Overall improvement | [10]https://pubmed.ncbi.nlm.nih.gov/15459533/ |
Small trial | 10 treated | Post-menopausal | 1 mg, daily | 52-82 weeks | Self-assessment and photographic assessment | Overall improvement (9/10 patients) | [11]Ahn J, Cho SB, Kim MN, Ro BI. Finasteride treatment of female patterned hair loss in postmenopausal women. Korean J Dermatol. 2006;44:1094-1097. |
Small trial | 6 treated | AGA, age 30-76 years (mean 46.5), normal androgen levels | 5 mg, daily | Weeks (not specified) | Retrospective questionnaire (self-assessment) | Overall improvement (5/6 patients) | [12]https://pubmed.ncbi.nlm.nih.gov/17454167/ |
Small trial | 37 treated | Female pattern hair loss, pre-menopausal, age 19-50 years (mean, 33.7) | 2.5 mg, daily (+ oral contraceptive drospirenone and ethinyl estradiol) | 12 months | Self-assessment, photographic assessment, and hair-density scoring | Overall improvement by self-assessment (29/37), photographic improvement ((23/37), significant hair density improvement (12/37) | [13]https://pubmed.ncbi.nlm.nih.gov/16549704/ |
Small trial | 41 treated | AGA, persistent adrenarche syndrome | 2.5 mg, daily (+ ethinyl estradiol) | 2 years | Not specified | Overall improvement | [14]https://pubmed.ncbi.nlm.nih.gov/19341939/ |
Small trial | 4 treated | 36, 40, 60, and 66 years old, elevated testosterone and hyperandrogenism | 1.25 mg, daily | 6 months to 2.5 years | Photographic assessment and self-assessment | Stabilization of hair loss within 6-12 months, hair growth improvements in 6 months – 2.5 years | [15]https://pubmed.ncbi.nlm.nih.gov/12399766/ |
Case study | 1 treated | 47-year-old, ‘male’ pattern hair loss, hysterectomy and ovariectomy, long-term hormone replacement | 2.5 mg, daily (+continued testosterone supplementation) | 10 months | Photographic assessment | Hair loss stabilization at 6 months, hair growth improvement at 10 months | [16]Hong JB, Chiu HC, Chan JY, Chen RJ, Lin SJ. A woman with iatrogenic androgenetic alopecia responding to finasteride. Br J Dermatol. 2007;156(4):754-755. doi:10.1111/j.1365-2133.2006.07719.x |
Case study | 1 treated | 67-year-old, 18 month history of hair thinning, normal androgen levels | 5 mg, weekly | 12 months | Self-assessment and photographic assessment | Improvement, hair regrowth | [17]https://pubmed.ncbi.nlm.nih.gov/12366441/ |
Case study | 1 treated | 51-year-old, 8 month history of hair thinning, normal androgen levels | 1 mg, daily | 12-13 months | Hair density measurements | Hair density increased versus baseline | [18]https://pubmed.ncbi.nlm.nih.gov/15844649/ |
There is conflicting data regarding the efficacy of finasteride for female pattern hair loss. Some studies report improvements while others do not.
There are some key variables to consider when weighing the available evidence:
Interpreting research data can be difficult and confusing. such as different studies using different dosages of finasteride and for varying lengths of time, measuring different hair loss outcomes, and using different numbers and ages of patients.
The specific type of hair loss is also a crucial variable.[19]https://pubmed.ncbi.nlm.nih.gov/30604525/ Often, studies reporting positive outcomes are based on patient self-reporting, which can be suspect and not meaningfully objective or quantitative in measuring true prevention or reversal of hair loss.
Given the dose-response relationship between finasteride and DHT levels, shouldn’t 1 mg be as effective as 5 mg? Why aren’t women getting consistent regrowth across doses within these ranges?
Other discrepancies are the time for which finasteride was given. In men, 1 mg of finasteride can be effective in 6-12 months, but it is possible that women require more long-term treatment regimens.[20]https://pubmed.ncbi.nlm.nih.gov/30604525/ Generally, success with finasteride in women has been reported in both the short- and long-term.[21]https://pubmed.ncbi.nlm.nih.gov/12399766/
Alternatively, the difference in observed efficacies between studies may be due to patient background and the type of hair loss. Hair loss in patients suffering from PCOS or adrenarche (i.e., high levels of adrenal gland activity) likely has a clear causal link to abnormal androgen signaling (and therefore suitable for finasteride), where hair loss in post-menopausal women may be more akin to age-related hair ‘thinning’, and not linked to testosterone or DHT, which may explain why some studies find no effect with finasteride.[22]https://pubmed.ncbi.nlm.nih.gov/10674382/[23]https://pubmed.ncbi.nlm.nih.gov/11050579/[24]https://pubmed.ncbi.nlm.nih.gov/12399766/
That said, finasteride is also reportedly effective in patients that are androgen-normal.20 Therefore, there needs to be more careful classification of the type of hair loss and the likely underlying mechanisms, as well as clear standardization of treatment outcome measurements.
Does finasteride work for women suffering from hair loss? If so, what is the ideal dosage?
Finasteride is most beneficial for women when their hair loss occurs alongside elevated androgen levels—much like hair loss in men.
It is likely that DHT is a major factor in a proportion of female hair loss cases. Finasteride is likely to be a beneficial part of a successful hair loss regimen in these cases. However, it is not clear that male and female pattern hair loss universally share the same underlying cause.
Finasteride may be less suitable in contexts of age-related hair thinning. Hair follicles are sensitive to all manner of different hormones and chemical signals, not just androgens such as testosterone and DHT.[25]https://pubmed.ncbi.nlm.nih.gov/32731328/
The best dose is one that maximizes the desired benefits (prevention and reversion of hair loss) while minimizing any undesirable side effects.
Finasteride can be effective at reducing DHT even in small doses. Because of this, experimentation with low levels of finasteride may lead to results with far less exposure to chemicals. Topical treatments may also be considered to further reduce systemic side effects.
Therefore, the best dose will be patient-subjective. Prior consideration of your history, goals regarding hair loss, and experimentation with dosages is needed before you will find the ideal routine for your hair health.
References[+]
↑1 | https://www.ncbi.nlm.nih.gov/books/NBK513329/ |
---|---|
↑2 | https://pubmed.ncbi.nlm.nih.gov/29407002/ |
↑3 | https://www.ncbi.nlm.nih.gov/books/NBK430924/ |
↑4 | https://europepmc.org/article/med/15319158 |
↑5 | https://www.fda.gov/drugs/information-drug-class/5-alpha-reductase-inhibitor-information |
↑6, ↑22 | https://pubmed.ncbi.nlm.nih.gov/10674382/ |
↑7, ↑8, ↑23 | https://pubmed.ncbi.nlm.nih.gov/11050579/ |
↑9 | https://www.tandfonline.com/doi/abs/10.3109/09546639709160517 |
↑10 | https://pubmed.ncbi.nlm.nih.gov/15459533/ |
↑11 | Ahn J, Cho SB, Kim MN, Ro BI. Finasteride treatment of female patterned hair loss in postmenopausal women. Korean J Dermatol. 2006;44:1094-1097. |
↑12 | https://pubmed.ncbi.nlm.nih.gov/17454167/ |
↑13 | https://pubmed.ncbi.nlm.nih.gov/16549704/ |
↑14 | https://pubmed.ncbi.nlm.nih.gov/19341939/ |
↑15, ↑21, ↑24 | https://pubmed.ncbi.nlm.nih.gov/12399766/ |
↑16 | Hong JB, Chiu HC, Chan JY, Chen RJ, Lin SJ. A woman with iatrogenic androgenetic alopecia responding to finasteride. Br J Dermatol. 2007;156(4):754-755. doi:10.1111/j.1365-2133.2006.07719.x |
↑17 | https://pubmed.ncbi.nlm.nih.gov/12366441/ |
↑18 | https://pubmed.ncbi.nlm.nih.gov/15844649/ |
↑19, ↑20 | https://pubmed.ncbi.nlm.nih.gov/30604525/ |
↑25 | https://pubmed.ncbi.nlm.nih.gov/32731328/ |
Latanoprost is a medication that was originally developed to treat glaucoma. Over the last two decades, research groups have also started testing it as a treatment for hair loss – including alopecia areata, androgenic alopecia, and telogen effluvium.
In this ultimate guide, we’ll explore the evidence on latanoprost, dive into the mechanisms and clinical data regarding hair growth, and identify who might be a good candidate for this experimental intervention. We’ll also specify which formulations, dilutions, and usage frequencies are reaping the best results in terms of both efficacy and safety.
Finally, we’ll uncover critical caveats with its use – including lesser-discussed (but significant) safety risks – and where to get latanoprost (should you choose to incorporate it into your regrowth regimen).
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Latanoprost is a drug developed to treat disorders of the eye – specifically, glaucoma. Originally formulated for delivery as eye drops, some users began reporting the elongation and/or regrowth of eyelash hairs.[1]https://jamanetwork.com/journals/jamaophthalmology/fullarticle/413134 Resultantly, researchers started investigating whether latanoprost – when formulated as a topical – might also enhance hair regrowth in other areas of the body, such as the scalp.
Latanoprost modulates levels of prostaglandin F2 – a substance our bodies produce that is derived from essential fatty acids (i.e., omega 6 fatty acids). More specifically, latanoprost stimulates the activity of the prostaglandin F2 alpha receptor. This allows for prostaglandin F2 levels to increase in cell sites, and when this occurs in eye tissues, it can reduce (or alleviate) ocular pressure and thereby improve cases of glaucoma.[2]https://www.ncbi.nlm.nih.gov/books/NBK540978/
There’s evidence that the eyelash hair regrowth reported by many latanoprost users isn’t just happenstance. For instance, as prostaglandin F2 activity increases…
Interestingly, many of the above mechanisms (i.e., improved vasodilation and prostaglandin modification) overlap with the suspected mechanisms of the FDA-approved hair loss drug, topical minoxidil. As such, it’s no surprise that in a case series on 300+ patients using eye drops of latanoprost to treat glaucoma, 77% saw hypertrichosis (i.e., additional hair growth) in the areas surrounding the eyes. [6]https://www.jaad.org/article/S0190-9622(01)70206-X/fulltext
With all of these cases, it’s also not out-of-the-question that latanoprost might also help regrow some scalp hair if reformulated as a topical.
In fact, this was corroborated by a 2002 study on primates (i.e., stump-tailed macaques) who happen to be one of the only other species to also suffer from pattern hair loss, or androgenic alopecia. Over an 8-month study, monkeys receiving a topical application of 0.5 ml x 0.005% to 0.05% latanoprost daily showed improvements to hair loss and cosmetic degrees of hair regrowth.
Fig. 1.Frontal bald scalp of a 10-year-old, female, macaque, showing sparce short vellus hairs in the bald scalp at pretreatment time (a). After 5 months of treatment with latanoprost 50 mg/ml, thickness and density of hair increased in upper central and lower lateral regions (b). After 3 months of latanoprost 500 ug/ml thickness and density of hair significantly increased in mid and lower lateral region.
Fig. 2.Sequential changes of average scores of categorical grades of hair growth in latanoprost and vehicle-treated monkeys.
The anecdotes on eyelash hair growth in glaucoma patients – and the preliminary evidence of hair regrowth on balding monkeys – certainly provides a strong enough signal to further investigate topical latanoprost as a hair loss treatment in humans.
So, over the last 20 years, what does the clinical evidence on latanoprost show?
While the data are limited (so far), clinical studies on latanoprost for hair loss have been conducted on both androgenic alopecia, telogen effluvium, and alopecia areata.
In its first-ever randomized, double-blinded, placebo-controlled clinical trial, researchers tested topical latanoprost on 16 men with early-stage androgenic alopecia.
Each participant received two drops of 0.1% latanoprost daily – one drop per receding temple region – equating to 0.1 mL of solution applied daily. In other words, each man applied 0.1 mg of latanoprost per day.[7]https://pubmed.ncbi.nlm.nih.gov/21875758/
Fig 1. Male subject with androgenetic alopecia (Norwood Hamilton scale grade III). Marked areas indicate minizone position for topical application of latanoprost and placebo solutions.
Over the course of 24 weeks, daily application of 0.1 mg of latanoprost…
The results were reflected statistically through phototrichogram data (i.e. the gold-standard for clinical research on hair loss disorders).
Fig 3. Number and percentage of anagen and telogen hairs/cm2 at baseline and 24 weeks. [8]https://pubmed.ncbi.nlm.nih.gov/21875758/
While the data seem encouraging, it’s important to point out three caveats. Across all latanoprost users:
In other words, latanoprost seemed to work well in half of participants, with the other half of participants showing hair loss stabilization or no response at all.
For what it’s worth, this is a common trait among hair loss drugs that target factors like histamine responses and/or prostaglandins – for instance, minoxidil and cetirizine. [9]https://perfecthairhealth.com/histamine-and-hair-loss-is-there-a-use-for-antihistamines/ For some, these drugs work wonders. For others, they see no effect. Why?
In our estimation, the dichotomies in responses are likely related to the following:
Therefore, this initial (albeit, small) clinical study on topical latanoprost suggests that it might have a place in treating some cases of hair loss, but not all.
In 2018, another research group investigated the use of topical latanoprost by itself (and combined with topical minoxidil) in the treatment of men and women with androgenic alopecia or telogen effluvium.[13]http://www.surgicalcosmetic.org.br/details/618/en-US/latanoprost-and-minoxidil–comparative-double-blind–placebo-controlled-study-for-the-treatment-of-hair-loss
First, the researchers split 123 participants into six groups, with each group testing one of the following:
Unfortunately, the investigators didn’t specify how much solution each participant applied once daily. Based on the photos of participants featured inside their study, many participants had moderate levels of hair loss and beyond, which would likely require at least 1-2 mL of solution to cover all balding regions. So, we can only make rough estimations as to how much daily exposure of these drugs each participant received.
Note: the absence of daily drug exposure volume is just one of the many flaws in this study. We’ll uncover more issues soon.
Over the course of 180-240 days, 25 of the 123 people withdrew from the study for reasons that the investigators state were “not related to the research” – though they don’t specify what those reasons were. Withdrawal rates were mostly equivalent across all six groups, which leaves us with 98 people and 16-18 participants per group for statistical comparisons.
Among those who remained, here are the key findings:
Here are some photos the investigators featured of participants using 5% minoxidil and 0.005% latanoprost – albeit from an extension period that ran up to 240 days:
Figure 1: Macro image of a female participant at the start and end periods (treatment with 5% minoxidil + 0.005% latanoprost)
Figure 2: Macro image of a male participant at the start and end periods (treatment with 5% minoxidil + 0.005% latanoprost)
And here is data regarding anagen hair counts (i.e., the number of “growing” hairs) across all groups and time periods (day 2, day 92, and day 182):
Graph 2: Number of anagen hairs by period and by treatment
First, let’s start off by interpreting a good signal from this study.
Topical formulations of latanoprost that are of higher volume and lower concentration might greatly minimize the risk of side effects.
If we recall from the 2011 study on topical latanoprost, two drops of 0.1% latanoprost totaling 0.1 mL of daily use led to skin irritation-related side effects in 50% of participants. But in this study on 0.005% to 0.01% latanoprost applied daily at 1-2 mL of volume, no adverse events were reported.
It might interest you to know that both of these studies likely exposed participants to the exact same total amount of latanoprost each day. It’s just that the 2011 study used a higher concentration (i.e., 0.1%) but with less volume of topical (i.e., 0.1 mL), whereas the 2018 study used a 10-20x lower concentration (i.e., 0.005% to 0.01%) but with 10-20x more volume (i.e., 1-2 mL).
Yet mathematically, both studies exposed their participants to ~0.1mg of latanoprost daily.
This is important, because it suggests that 0.1mg of latanoprost may become a lot more tolerable for hair loss patients when it is spread out over a larger area. So, if nothing else comes from this study, we’re at least encouraged by this signal.
So what else can we surmise?
1-2 mL daily of 0.005% latanoprost may improve hair counts for a portion of people with androgenic alopecia and/or telogen effluvium… particularly if combined with 5% minoxidil
According to the data presented by the research team, 0.005% latanoprost by itself was effective at improving hair parameters, as was 0.005% latanoprost + 5% minoxidil.
However, we need to keep in mind the response rates here: just 35% to 36% of participants in these groups saw visual regrowth. That’s not a lot, and it gives credence to the belief that while latanoprost might work for some people, it’s probably not appropriate for all hair loss sufferers.
Looking at all of the data from this study can be confusing. After all, we have 6 different groups statistically measured across one another, with varying methodologies applied for some groups (like extension time periods for those using 0.005% latanoprost + 5% minoxidil), and with poor clarity in writing regarding both results and discussion organizations.
Nonetheless, we’ve read online about some people presuming that this study gives us enough insights to include the following. So, before adopting similar opinions, please read our counterarguments below:
Fallacy #1: this study suggests that 0.01% latanoprost might be less effective than 0.005% latanoprost
It’s not abnormal to make this assumption given the data presented. After all, the groups using 0.005% latanoprost saw a 35% and 36% response rate, whereas the groups using 0.01% latanoprost saw a 6% and 0% response rate.
Moreover, it’s not unusual to see dose-dependent effects in medicine – where some drugs have a strong therapeutic benefit at lower concentrations but can have opposing or toxic effects at higher concentrations. We discuss these relationships in our guide on flutamide.
Nonetheless, there are significant methodological flaws in this study that do not allow us to jump to this conclusion. Here are a few:
As such, we need to be incredibly careful about drawing any efficacy or comparison conclusions from this study. It’s entirely possible that 0.005% and 0.01% latanoprost are equally effective… but that the groups receiving higher dilutions of latanoprost had poorer results because of participant sampling. Without better data, we just don’t know.
As an aside, when discussing this study across our own team, we were even apprehensive to mention the positive safety signal – as this 2018 study is so poorly designed that any conclusions whatsoever are potentially problematic and/or at-odds with the real-world experiences of latanoprost users.
Nonetheless, we have to work with the data currently available, and these two studies on topical latanoprost are all that we’ve got (so far) for androgenic alopecia.
So, what about other hair loss disorders, such as alopecia areata?
To date, there have been five publications (to which we could find) assessing topical latanoprost for alopecia areata. Here are their quick summaries and results:
A 2003 case report details the experience of an 11-year old female who experienced alopecia areata of the eyelashes after recovering from a viral illness. After multiple failed treatments, doctors eventually tested topical latanoprost – at an unknown dilution – which was applied daily for a period of six months. During that time, photographic assessments show a near full recovery of all lost eyelashes.[14]https://pubmed.ncbi.nlm.nih.gov/12724722/
A 2009 clinical study tested 0.005% latanoprost – at an unknown volume – on a total of 26 men and women with alopecia areata of the eyebrows and eyelashes. Participants applied latanoprost to just one side of the face, with the other side acting as an intra-patient “control”. After four months, researchers saw partial hair recovery in just one patient, and concluded that topical latanoprost was no more effective than applying nothing at all. Aside from a transient headache fro one patient, no adverse events were reported.[15]https://pubmed.ncbi.nlm.nih.gov/19620039/
Interestingly, these results were mirrored by prior clinical studies done on similar dilutions of topical latanoprost for eyelash-related alopecia areata from 2005 and 2008.[16]https://pubmed.ncbi.nlm.nih.gov/16310083/[17]http://www.iranjd.ir/article_98048_64fda5d6552e3e9d714cc2162d5686a4.pdf As such, it appears that the data (so far) suggest topical latanoprost does not improve this specific hair loss disorder for the overwhelming majority of people trying it.
Finally, a 2021 randomized clinical study tested daily applications of 0.005% latanoprost versus 0.05% betamethasone diproprionate (an autoimmune-related medication) for the treatment of scalp-related alopecia areata in 50 patients.[18]https://ijdvl.com/a-randomized-comparative-study-of-the-efficacy-of-topical-latanoprost-versus-topical-betamethasone-diproprionate-lotion-in-the-treatment-of-localized-alopecia-areata/
Unfortunately, the researchers did not specify the amount (in mL) of topical applied daily. As such, we cannot estimate daily exposure volumes.
Over a 16-week period, 24% of patients using 0.005% latanoprost saw improvements, whereas 56% of patients using 0.05% betamethasone diproprionate saw improvements. In fact, patients in the 0.05% betamethasone diproprionate group also tended to see a faster recovery and a more dramatic reduction of alopecia areata lesions.
Therefore, the researchers concluded that 0.05% betamethasone diproprionate was superior to 0.005% latanoprost in the treatment of scalp alopecia areata.
From what we can glean across all clinical studies on topical latanoprost for hair loss:
It’s easy to look at these studies and note that dilutions of 1-2 mL daily of 0.005% to 0.01% were well-tolerated for nearly all participants, with only a handful of minor, transient adverse events reported across all patient cohorts testing this formulation. As such, it’s easy to presume that topical latanoprost must be safe.
We have significant reservations with that conclusion.
After all, these topical latanoprost studies for hair growth ran – at most – 8 months. While no serious adverse events were reported during these short timeframes, there is a well-known phenomenon that occurs from long-term latanoprost use, and one that does not typically show up until after one full year of treatment: pigment changes.
In glaucoma patients, pigment changes of the iris begin to occur after one year of daily latanoprost use, and they worsen over time – affecting up to 10% of glaucoma patients.[19]https://www.ncbi.nlm.nih.gov/books/NBK540978/ Other studies suggest an incidence as high as 70%, depending on the eye color & duration of use.[20]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771317/
This is because regular latanoprost use increases melanin activity (i.e., the activity of cells that produce pigmentation in our skin, eyes, etc.). The effects, over time, can be quite dramatic. Just see the results from this patient, who was treated for glaucoma in their right eye with latanoprost (picture A) but not in their left eye (picture B). It’s as if we are looking at two different eyes. [21]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771317/
As such, a critical question remains: does latanoprost applied topically produce the same effects in the skin, hair, and (potentially) through the eyes via systemic absorption?
Unfortunately, we have no way of knowing… because the clinical studies have not yet been conducted. Moreover, none of the studies on topical latanoprost for hair loss ran even remotely long enough to measure if this effect would also apply to the scalp.
In cases of treatments producing serious, cosmetically-unwanted adverse events – like a darkening of scalp skin – we tend to err on the side of caution and say that without more data, most people should be seriously cautious about long-term use of topical latanoprost. Perhaps better data will demonstrate this is not a concern, but until we have that data, we don’t feel comfortable recommending topical latanoprost as a guinea pig experiment to members here… even despite its popularity online as an adjuvant hair loss treatment.
For more contraindications and side effects from latanoprost, please visit this resource.[22]https://www.ncbi.nlm.nih.gov/books/NBK540978/
You are likely a candidate for latanoprost if:
You are likely not a candidate for latanoprost if:
Latanoprost has some limited clinical data supporting its use for androgenic alopecia, but with response rates of 30-50%, it’s unlikely that this treatment is right for most hair loss sufferers. For these reasons, we recommend people use other prostaglandin analogues instead – such as minoxidil – and only resort to latanoprost if they’re using it as an add-on to their regimen and if they’re comfortable with the unknowns about its long-term safety profile.
For alopecia areata of the eyelashes, latanoprost is unlikely to help. For alopecia areata of the scalp, one small study found that topical latanoprost may help up to 25% of people. However, that same study also found that 0.05% betamethasone diproprionate was twice as effective at producing a response rate versus latanoprost, and that it also worked faster than latanoprost.
References[+]
↑1 | https://jamanetwork.com/journals/jamaophthalmology/fullarticle/413134 |
---|---|
↑2, ↑19, ↑22 | https://www.ncbi.nlm.nih.gov/books/NBK540978/ |
↑3 | https://pubmed.ncbi.nlm.nih.gov/15854125/ |
↑4 | https://www.frontiersin.org/articles/10.3389/fphys.2020.594313/full |
↑5 | https://pubmed.ncbi.nlm.nih.gov/33854354/ |
↑6 | https://www.jaad.org/article/S0190-9622(01)70206-X/fulltext |
↑7, ↑8 | https://pubmed.ncbi.nlm.nih.gov/21875758/ |
↑9, ↑11 | https://perfecthairhealth.com/histamine-and-hair-loss-is-there-a-use-for-antihistamines/ |
↑10 | https://pubmed.ncbi.nlm.nih.gov/8496421/ |
↑12 | https://my.perfecthairhealth.com/courses/minoxidil/topical-minoxidil/ |
↑13 | http://www.surgicalcosmetic.org.br/details/618/en-US/latanoprost-and-minoxidil–comparative-double-blind–placebo-controlled-study-for-the-treatment-of-hair-loss |
↑14 | https://pubmed.ncbi.nlm.nih.gov/12724722/ |
↑15 | https://pubmed.ncbi.nlm.nih.gov/19620039/ |
↑16 | https://pubmed.ncbi.nlm.nih.gov/16310083/ |
↑17 | http://www.iranjd.ir/article_98048_64fda5d6552e3e9d714cc2162d5686a4.pdf |
↑18 | https://ijdvl.com/a-randomized-comparative-study-of-the-efficacy-of-topical-latanoprost-versus-topical-betamethasone-diproprionate-lotion-in-the-treatment-of-localized-alopecia-areata/ |
↑20, ↑21 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771317/ |
Finasteride is a hair loss drug for treatment of androgenic alopecia. It inhibits the 5-alpha reductase type II enzyme that converts testosterone into dihydrotestosterone, or DHT.
Topical finasteride formulations (think: solution, spray, or gel) are growing in popularity because of their localized approach. Oral finasteride reduces DHT everywhere in the body. Topical finasteride reduces DHT in the area that it is applied while minimizing systemic absorption. That is, if you apply it correctly. The question of how to apply topical finasteride for the greatest benefit and the least systemic absorption has no single, easy answer.
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Strategies for applying topical finasteride depend on its formulation (spray, solution, serum, or gel). We’ll review those first, then explain how long topical finasteride needs to stay on the scalp in order to absorb and have an effect (hint: it depends on the dosage and carrier agent).
Many hair loss sufferers opt for topical finasteride spray. These sprays are often used to disperse the drug over wide surface areas of scalp skin, and are most appropriate for people with (1) thinning over widespread areas who also (2) are keeping their hair very short so that the scalp skin is easily accessible.
If you have diffuse thinning and longer hair, sprays might not be right for you. This is because too much of the topical finasteride will end up on the hair (where it does nothing) rather than the scalp (where hair grows from).
Users are advised to hold the spray bottle 2-3 inches from the scalp and apply the prescribed amount on the crown, top, and front of their heads. The hands can then be used to rub in any liquid blocked by existing hairs. This will ensure that a considerable amount of the formula has reached the scalp, particularly in problem areas.
Some users prefer to spray the formula into their palms and apply it manually with their fingertips. As with other formulas, parting sections of hair may make it easier to apply.
Topical finasteride is also prescribed in the form of a liquid solution. These variations may include minoxidil as a combination therapy. Such formulas typically include a dropper for easy application. To apply the solution, part the hair in sections, apply a few drops along the part, then rub the solution around the scalp skin with the fingertips. Additional drops can then be applied to key problem areas (crown, top, and both sides of the front).
Alternatively, the prescribed amount can be dispensed into the hand and applied manually.
Gel formulations are often made of bases of silica and/or liposomes. They’re very popular, as they are easy to apply. For best results, users can start with a few pumps of the gel, applying with their hands to provide even coverage across each problem area. The gel should gently be massaged into the scalp for 30 seconds or more.
No matter the treatment form, it’s only necessary to cover the areas affected by hair loss. Users should always follow their doctor’s recommendations and consult the directions included in their formula.
Any excess formula should immediately be washed off of hands and other areas of the body.
How long to let topical finasteride sit on your scalp depends on several factors, including:
To understand more of this process, we also need to understand the stages of absorption when applying any drug to our scalp skin:
An in vitro study measured percutaneous absorption of topical finasteride across a variety of different formulations: ethosomes, ethanol, liposomes, and aqueous (water). [1]ncbi.nlm.nih.gov/pmc/articles/PMC2977015
This chart shows the percent of topical finasteride that percutaneously absorbs (enters the dermis) over a 24-hour period:
Penetration profiles of finasteride permeating through human skin from different preparations (mean ± SD, n = 4)
There are three big takeaways from this chart:
Leaving finasteride on the scalp for 10 hours allows for 5 micrograms per square centimeter of percutaneous absorption across most carrier agents. Is this enough finasteride to therapeutically lower scalp DHT levels? More importantly, is it enough to regrow hair?
There is not a clinical study that attempts to answer this. However, there is some surrogate data to help us approximate the answer.
A certain percentage of topical finasteride will absorb into the dermis. The bloodstream will absorb some of this later. Time-dependent DHT reductions in the bloodstream can be used to “ballpark” how much DHT is likely also being reduced in the scalp. This is because there is more topical finasteride that percutaneously absorbs than systemically absorbs. For lower dosages, the effects we see in the system can be used as signals for what’s happening – at a minimum – in the scalp skin.
This figure from a 2014 study measures the effects of one versus two applications of 1 mL of 0.25% topical finasteride on serum DHT levels. [2]https://pubmed.ncbi.nlm.nih.gov/25074865/
Caserini, M., Radicioni, M., Leuratti, C., Annoni, O., & Palmieri, R. (2014). A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. International journal of clinical pharmacology and therapeutics, 52(10), 842–849.
Six hours after applying 1 mL or 2 mL applications of 0.25% topical finasteride (i.e., 2.275-4.550 mg of finasteride), serum DHT reductions flatline. By the 6-hour mark, the 2ml application group experienced roughly the same serum DHT reductions as would be expected from a 1mg oral dose of finasteride.
Finasteride has an upper limit for its effects on serum DHT reduction. After ~70% reduction in serum DHT, adding more finasteride doesn’t reduce more serum DHT. The same is true with scalp DHT reductions.
Topical finasteride applications of 2.275 mg or higher (with a hydroxypropyl chitosan delivery vehicle) achieve systemic reductions in DHT. Furthermore, the larger dose of topical finasteride reduces systemic DHT levels on par with oral finasteride.
Serum DHT reductions are only achieved after scalp DHT reductions occur. Because of this, the conclusion can be drawn that 6-12 hours after applying topical finasteride, there’s likely enough percutaneous absorption to therapeutically lower scalp DHT levels for hair regrowth. However, this time window depends on a number of factors, including:
The next logical question becomes, just how low of a dilution of finasteride can you apply to evoke hair growth outcomes, while still potentially preserving serum DHT levels to the best of your ability? Interestingly, there seems to be a “sweet spot” for this at ~0.1 mg daily of topical finasteride mixed with alcohol and propylene glycol as carriers.
A 1997 study corroborates this. The study suggests that 2 mL daily of 0.005% topical finasteride (i.e., 0.0912 mg of finasteride exposure) improved hair parameters for men with AGA. This was achieved without affecting serum DHT levels – even after 16 months of treatment. [3]https://www.tandfonline.com/doi/abs/10.3109/09546639709160517
Most big-brand topical finasteride companies are:
For most users, this will equate to 1 mg to 6 mg of topical finasteride exposure daily – which is more than 100x the minimum viable dose of topical finasteride. At these dosage ranges, the evidence suggests that topical finasteride will only need 6-12 hours on the scalp to therapeutically lower scalp DHT levels and start encouraging hair growth.
Topical finasteride users should use this time window to their advantage! But they should also keep in mind that, at most big-brand dose ranges, they’re exposing themselves to just as much (if not more) finasteride than the oral formulations. So they might be overpaying for topical finasteride in hopes of “localizing” its effects, only to also have just as much – if not more – of that drug going systemic.
To get the true benefits of localization, users will likely need to drop their dose as low as 0.005% x 2 mL daily, and periodically track serum DHT levels to ensure systemic effects are minimal.
The instructions on the packaging aren’t always as precise as the research. Best to trust the science when it comes to how to apply topical finasteride for maximum effectiveness, and minimal side effects.
References[+]
According to 2021 estimates, over 20% of people in the U.S. use antidepressants or antianxiety medications. Within this group of medications, hair loss is sometimes listed as a known side effect.
Mostly, these drugs cause temporary hair loss that goes away after a period of acclimation or after the drug is discontinued. But for the 1 in 5 people who use these drugs to support mental wellbeing, there’s a very real fear that mood stabilization might only be available at the expense of their hair.
The good news is that hair loss from anxiety medications is relatively uncommon. And while it can occur, there are ways to mitigate the risk of hair fall.
This article takes a scientific look at the relationship between the most commonly prescribed psychotropic drugs and hair loss, revealing science-based recommendations for those who are affected by hair loss and worried that their antidepressants are to blame.
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Drug-induced alopecia typically falls into two main categories: telogen effluvium and anagen effluvium. These names refer to the stage in the hair cycle where growth is interrupted.[1]https://link.springer.com/article/10.2165/00002018-199410040-00005
Telogen effluvium is the most common type of drug-induced hair loss. With this condition, hair follicles are prematurely triggered to enter their resting (telogen) phase, which induces early shedding. The condition typically becomes noticeable within 2-4 months of beginning treatment.
Anagen effluvium occurs during hair’s growth (anagen) phase. Hair cells that should be rapidly dividing are triggered to abruptly stop. This type of drug-related hair loss occurs within days or weeks of treatment and is not limited to the scalp. It is most commonly associated with chemotherapy drugs.
Medication-induced alopecia, in particular telogen effluvium, is a known side effect of some psychopharmaceuticals. Hair loss is typically temporary and may resolve on its own, or with a reduction in dosage. Discontinuation of these drugs nearly always leads to hair regrowth.[2]https://pubmed.ncbi.nlm.nih.gov/10798824/
Psychopharmaceuticals do not cause androgenic alopecia (male pattern baldness), but may temporarily accelerate the condition. If several hair follicles in AGA-prone regions suddenly enter the telogen phase, hair follicle miniaturization can increase, speeding the progression of AGA.
It’s important to note that just because hair loss is listed as a potential side effect of certain medications does not mean it will happen to everyone. But, it can still happen. What’s most important is the percent of people reporting hair loss in a clinical trial for any of these drugs.
Among the class of drugs referred to as psychopharmaceuticals, hair loss is most frequently associated with long-term use of lithium and valproic acid.
As many as 19% of lithium users and 12% of valproic acid users report the unwanted side effect.[3]https://pubmed.ncbi.nlm.nih.gov/10798824/ For most other drugs, risk is much lower, and possibly as low as 0.01%.
To learn more about the actual connection between antidepressants, anti-anxiety medications, mood stabilizers and hair loss, the Perfect Hair Health team combed through hundreds of case studies.
First, the team looked at the most commonly prescribed medications and then ran those drug names through a research database to pull up any and all studies that mentioned hair loss. Below is an overview of what was found.
If a drug is not the list, it’s either because no reports of hair loss were not found or commonly prescribed. Others were simply not worth mentioning for various reasons. To jump to a particular drug, use the links below.
Antidepressants
Anti-Anxiety Medications
Of the several studies cited below, most consist of case reports that reference just a single individual. What’s more, these case reports often make it to publication precisely because of their uniqueness. In these reports, researchers often make reference to ‘the first known case’ or ‘the only known case.’
Case studies rank relatively low on the hierarchy of evidence, as they are very anecdotal, and not supported by double-blind research, for example. This makes it hard to know the true incidence or prevalence of hair loss from many of these drugs.
Antidepressants are of several different classes, namely selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), MAOIs, and atypical medications.
Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed antidepressants and are sometimes used to treat anxiety disorders. Of these, hair loss is associated with the following medications:
The team did not find any studies linking two other common SSRIs, protriptyline (Vivactil) and amitriptyline (Elavil) with hair loss. Take a closer look at what was found.
2021 Case Study:
A male patient diagnosed with major depressive disorder experienced hair loss with escitalopram. The patient discontinued escitalopram when he could no longer tolerate the hair loss. The hair loss stopped within one month.[4]https://www.psychiatria-danubina.com/UserDocsImages/pdf/dnb_vol33_no2/dnb_vol33_no2_187.pdf
2020 Case Report:
A female patient on 5mg escitalopram reported minor hair loss. After her dose was increased to 10mg, hair loss became ‘significant.’ After quitting the drug due to intolerable hair loss her symptoms ‘dramatically’ resolved within one week.[5]https://www.psychiatrist.com/pcc/depression/escitalopram-induced-hair-loss/
2016 Case Study:
This case study is unusual because the female patient presented with eyelash loss 12 weeks after beginning treatment with escitalopram. Her eyelashes returned to near normal 5 weeks after she stopped taking the medication.
While SSRIs are known to cause alopecia, this is the first reported case of eyelash loss. Researchers noted the timing of the patient’s presentation was consistent with the growth cycle of eyelashes, suggesting the mechanism of loss was interruption of the hair growth cycle.[6]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035805/
Norton DJ, Cates C. Eyelash Loss Secondary to Escitalopram But Not to Sertraline: A Case Report. Prim Care Companion CNS Disord. 2016;18(3):10.4088/PCC.15l01887. Published 2016 May 19.
2011 Case Study:
Woman suffering from major depressive disorder noticed hair loss 3 weeks after beginning escitalopram. She discontinued the drug due to intolerable hair loss. Two weeks later, the hair loss stopped.
Several months later she tried the drug again as her depressive symptoms had returned. After 2 weeks? Her hair loss returned.[7]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219523/
2021 Case Study:
Six weeks after beginning fluoxetine, a male patient reported hair loss in the frontal region of the skull. His complaints ended after he stopped taking the drug. This case appears to be the first evidence of fluoxetine-related hair loss in men.[8]https://pubmed.ncbi.nlm.nih.gov/34355374/
2019 Case Study:
Six weeks after beginning fluoxetine, a female patient reported hair loss in the frontal region of the skull.[9]https://pubmed.ncbi.nlm.nih.gov/31599441/
2018 Case Report:
Female patient notices significant hair loss 2 weeks after beginning fluoxetine. By 18 months, she had lost all her scalp and body hair. Researchers are aware of just one other similar case, and suggest there may be a wider spectrum of fluoxetine-related hair loss than previously known.[10]https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/hair-loss-associated-with-fluoxetine/D2A55E09DDCF393399C14DB9289BAADE
2004 Case Study:
Female patient reports slight hair loss 3 months after beginning fluoxetine 20mg treatment. Reducing the drug to 10mg had no effect on her hair loss. After 1 year she stopped treatment due to intolerable hair loss on the scalp and body. 4 weeks later, her hair returned to normal thickness.[11]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC514846/
1992 Drug Trial:
A group of 15 young adults, ages 16-24, trialed fluoxetine for the treatment of their depression. Researchers noted that the side effect of alopecia appeared more commonly than in adult studies.[12]https://pubmed.ncbi.nlm.nih.gov/19630647/
2021 Case Report:
Male with social anxiety disorder reports hair loss after beginning treatment with paroxetine. The hair loss stopped after discontinuing the drug, then recurred when treatment with paroxetine began again.[13]https://pubmed.ncbi.nlm.nih.gov/34181746/
2006 Case Study:
Over 60% of patients with alopecia areata (AA) have a psychiatric comorbidity. Researchers hypothesize that treating this depression may have a positive effect on hair growth. In this case study, a female patient had complete hair regrowth 7 weeks after beginning paroxetine treatment. One month after discontinuing the drug, her symptoms of AA had returned.[14]https://sci-hub.se/https://pubmed.ncbi.nlm.nih.gov/16922952/
2001 Double-Blind Randomized, Placebo-Controlled Trial:
A group of 13 patients presenting with AA and a psychiatric comorbidity were studied to see if treatment with SSRIs could lead to regrowth of hair. Researchers observed the complete regrowth of hair in two patients treated with paroxetine, while four showed partial regrowth. Meanwhile, only one patient from the placebo group had similar regrowth.[15]https://pubmed.ncbi.nlm.nih.gov/11737460/
2000 Case Report:
‘Massive’ hair loss was reported in a woman being treated with paroxetine, which improved soon after she stopped taking the drug.[16]https://pubmed.ncbi.nlm.nih.gov/10883182/
1999 Case Report:
A female complained of ‘moderate’ hair loss after beginning paroxetine treatment. The hair loss stopped after discontinuing the drug, and began again when the drug was reintroduced.[17]https://pubmed.ncbi.nlm.nih.gov/10442258/
2015 Case Study:
A male patient reports hair loss 2 weeks after beginning sertraline treatment. His hair loss improved after he stopped taking the drug.[18]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589582/
2008 Case Study:
A woman complained of hair loss during sertraline treatment. This case is unique because she had previously been treated with fluoxetine, but reported no hair loss during that treatment.[19]https://pubmed.ncbi.nlm.nih.gov/18664165/
2006 Literature Review:
Researchers reviewed all reports of SSRI-induced hair loss in the national Swedish database and the database for the World Health Organization. Reports of sertraline-induced hair loss were nearly double those for citalopram, although still considered a ‘rare’ side-effect.[20]https://pubmed.ncbi.nlm.nih.gov/16783834/
2005 Case Study:
A 14 year old boy reports hair loss after 5 years of sertraline treatment. The drug was gradually discontinued and the hair loss stopped.[21]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000200/
Bupropion is an atypical antidepressant. It is not an SSRI or an SNRI, but an NDRI. It’s used not only to treat depression, but sometimes prescribed to help with smoking cessation.
2018 Research:
In a study that followed over 1 million patients, researchers tracked exclusive users of antidepressants to better understand hair loss risk. They found that compared with bupropion, all other antidepressants had a lower risk of hair loss. Fluoxetine and paroxetine ranked as being lowest risk, with the highest level of confidence.
The researchers concluded that of all the SSRIs and SNRIs, bupropion has the highest risk of hair loss, while paroxetine has the lowest.[22]https://pubmed.ncbi.nlm.nih.gov/28763345/
Olanzapine and quetiapine are classified as atypical antipsychotics. Both are used in the treatment of bipolar disorder, while quetiapine is also sometimes used to treat major depressive disorder.
2002 Case Report:
After increasing her daily dose of olanzapine from 5mg to 15mg daily, a woman reports increasing hair loss. Hair loss discontinued after switching from olanzapine to risperidone. Researchers report that this is the first known case of olanzapine-induced hair loss, and note the manufacturer, Eli Lily Canada, estimates hair loss occurs among just 0.01% of users.[23]https://sci-hub.se/https://pubmed.ncbi.nlm.nih.gov/12500769/
2007 Literature Review:
Researchers reviewed all case reports of alopecia following quetiapine treatment reported to the New Zealand Intensive Medicines Monitoring Programme and the World Health Organization. They found 17 cases total, some of which support a causal relationship between quetiapine and hair loss. Researchers note that while hair loss has previously been associated with both olanzapine and risperidone, it has not yet been described with quetiapine.[24]https://pubmed.ncbi.nlm.nih.gov/17293712/
Benzodiazepines are classified as depressants and can help patients who struggle with anxiety. Of this class of drugs, only clonazepam seems to be associated with hair loss. There were no studies connecting alprazolam (Xanax), diazepam (Valium) or lorazepam (Ativan) with hair loss.
2009 Case Study:
A woman complains of hair loss one week after beginning treatment with clonazepam. The hair loss stopped when she stopped taking the drug. Researchers note they reviewed the literature and found only one other case of hair loss associated with clonazepam. Also noted, she had been taking escitalopram (which has a more well-documented association with hair loss) prior to her hair shedding and continued with this drug even as her hair grew back.[25]https://pubmed.ncbi.nlm.nih.gov/19471188/
Busiprone is categorized as an anxiolytic, and is used to treat both short-term and chronic anxiety.
2013 Case Report:
A woman being treated with buspirone and sertraline reports significant hair loss. Her treatment team discontinued buspirone, but not sertraline (which is also associated with hair loss). The patient reported her hair loss stopped 3-5 days later, although researchers noted they couldn’t confirm.[26]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579479/
Antimanic agents are mood stabilizers. They are used in the treatment of bipolar disorders and can calm those in states of mania or extreme anxiety. Of this class of drugs, lithium and valproic acid are most frequently associated with hair loss.
2013 Literature Review:
A meta analysis on the side effects of lithium finds no statistically significant increase in risk of hair loss with lithium treatment. Researchers mention that lithium suppresses the thyroid, which could be related to reports of hair loss.[27]https://pubmed.ncbi.nlm.nih.gov/23525591/
2012 Literature Review:
A review of 385 abstracts were screened for reports of lithium toxicity, including lithium-induced alopecia. Researchers found no significant risk of alopecia associated with lithium.[28]https://pubmed.ncbi.nlm.nih.gov/22265699/
1994 Case Study:
A woman reports hair loss after beginning lithium treatment. 2 months after discontinuing treatment, her alopecia resolved. Researchers note this side effect is rare.[29]https://pubmed.ncbi.nlm.nih.gov/7995585/
1988 Case Study:
A patient reports total hair loss after 2 months of lithium treatment. Researchers discuss a possible connection between the drug and alopecia totalis.[30]https://pubmed.ncbi.nlm.nih.gov/3126095/
1984 Literature Review:
Researchers review all cases since 1970, when lithium-related hair loss was first reported. They suggest patients experiencing hair loss after lithium treatment be checked for hypothyroidism, because lithium ions may concentrate in the thyroid, disrupting normal processes in this area.[31]https://pubmed.ncbi.nlm.nih.gov/6519870/
1983 Case Report:
Of 100 patients on lithium therapy, 12 report hair loss. 1 patient was diagnosed with hypothyroidism, others experienced hair regrowth after discontinuing treatment.[32]https://pubmed.ncbi.nlm.nih.gov/6838778/
1983 Case Study:
Researchers present 2 cases of hair loss attributed to lithium therapy. They recommend thyroid tests to exclude hypothyroidism as the cause of hair loss.[33]https://pubmed.ncbi.nlm.nih.gov/6404546/
1982 Case Report:
Researchers study 7 cases of hair loss associated with lithium. They mention other findings that for those with scalp psoriasis, lithium can aggravate this condition. They report findings consistent with telogen effluvium and conclude lithium can cause increased hair shedding. [34]https://pubmed.ncbi.nlm.nih.gov/6809028/
2018 Case Study:
A review of over 400,000 patients being treated with psychotropic drugs in German-speaking countries found that Valproic acid was related to the highest risk of hair loss. That said, researchers found just 43 cases, a number distinctly lower than expected.[35]https://pubmed.ncbi.nlm.nih.gov/30193142/
2018 Literature Review:
A review of literature finds Valproate-induced hair loss is diffused, nonscarring, and dose-related. The drug may also cause graying and changes to hair texture. Researchers note that topical valproic acid may help hair regeneration and suggest further study into the difference between oral and topical administration as they relate to changes in hair growth.[36]https://pubmed.ncbi.nlm.nih.gov/30386073/
2017 Research:
Hair loss is a well-known side effect of valproic acid. It leads to telogen effluvium and appears to be dose-dependent, meaning hair loss increases with increased dosage. Paradoxically, valproic acid can be applied topically to help regrow hair. Researchers explore this paradox.[37]https://pubmed.ncbi.nlm.nih.gov/29061425/
2017 Research:
Valproic acid is often administered to patients undergoing radiation therapy for brain tumors to help manage seizures. Doctors note that delay or prevention of hair loss in this population seems to be a positive side effect.[38]https://pubmed.ncbi.nlm.nih.gov/27889835/
1996 Literature Review:
A 1996 literature review finds that alopecia is a common side effect of treatment with antimanic agents, and is expected in up to 12% of patients undergoing treatment with valproate, and 10% of patients being treated with lithium.[39]https://pubmed.ncbi.nlm.nih.gov/8899137/
1992 Case Report:
Two reports with seemingly conflicting results. In one, lithium-induced hair loss improved when lithium was replaced by valproate. In the other, hair loss improved only after stopping valproate.[40]https://pubmed.ncbi.nlm.nih.gov/1486112/
The above case studies offer evidence that the relationship between psychopharmaceuticals and hair loss may be more nuanced than expected.
Case reports are justifiably considered a weaker form of evidence. In other words, they rank low on the hierarchy of evidence. While case studies (i.e., n=1 published anecdotes) offer ‘signals’ for scientists to explore in future randomized controlled clinical trials, they also come with a high risk of bias. Case studies don’t establish prevalence rates, and it’s always possible that patients in these reports were using other medications and/or experienced additional life events that might also explain their hair loss. While they indeed contribute to future research, using case studies to interpret cause and effect is difficult.
The bottom line? It’s not always easy to say, ‘this drug causes hair loss.’
Hair loss can have many causes, making a causal relationship between a single drug and hair loss very hard to prove. In some of the above studies on SSRIs, researchers tried to hone in on this relationship by stopping treatment, seeing if the hair grew back, and then rechallenging the patient with the same medication to see if their hair loss then returned.
While this process occurred in a few of the case studies found, more research must still be done, as the sample size in the studies mentioned here consists of just a few people.
Another way to explore the existence of cause-and-effect is to dive more deeply into possible causes outside of the drug. Basically, one must rule out the following:
Patients receiving treatment for depression and anxiety may have other comorbidities or may be taking more than one medication.
Some of the case studies above report this, others make it clear the patient was an ‘exclusive user’ of the drug in question, while others make no such reference to either.
It’s possible that even in cases where one medication was discontinued and hair loss subsequently stopped, that it was the interaction between one or more drugs, and not a single drug, that triggered the onset of hair shedding.
Several of the studies on lithium, which is widely described as a drug which ‘causes’ hair loss, mentioned patients who had pre-existing skin conditions, particularly scalp psoriasis. While it may be true that they experienced alopecia only after beginning lithium treatment, the root cause of hair shedding could have been their psoriasis.
Several patients in the above case studies had also experienced alopecia in the past. Alopecia is an embarrassing condition which can lead to depression and anxiety. Also, those with depression and anxiety may be predisposed to alopecia. Researchers estimate that up to 30% of patients with skin conditions have psychiatric comorbidity.[41]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756276/
Of the case reports presented here, researchers often (but not always) confirmed the patient’s own reports of hair loss and hair regrowth. In just one instance was there mention of blood drawn to confirm the patient was indeed taking only the medication prescribed, as directed.
Particularly regarding the anti-anxiety medications, some patients presented with symptoms of schizophrenia. Hair pulling, or trichotillomania, must be ruled out in those cases and others.
Understanding the mechanisms of action can also help establish cause and effect. While it’s still unknown exactly how these medications induce hair loss, the following are a sample of the most plausible theories.
Psychotropic drugs typically cause diffuse, reversible alopecia by influencing hair’s telogen (shedding) phase.[42]https://pubmed.ncbi.nlm.nih.gov/10798824/ The exact mechanism via which this works has yet to be revealed, although it may be connected to the relationship between serotonin and melatonin.
Serotonin is a precursor to melatonin, but the two also work in tandem to regulate a healthy circadian cycle. SSRIs in particular may decrease melatonin, which plays a role in hair cycle control.[43]https://pubmed.ncbi.nlm.nih.gov/16217127/
Slominski A, Fischer TW, Zmijewski MA, Wortsman J, Semak I, Zbytek B, Slominski RM, Tobin DJ. On the role of melatonin in skin physiology and pathology. Endocrine. 2005 Jul;27(2):137-48.
Lithium and other antimanic agents may exacerbate hypothyroidism. While lithium cannot seem to shake its reputation as a cause of hair loss, researchers do not necessarily believe that lithium is the direct cause. Rather, it seems that hypothyroidism (caused by lithium) is to blame. Insufficient thyroid hormone can trigger telogen effluvium.
With lithium and some other psychopharmaceuticals, dosage plays a role in determining risk for hair loss. Some patients who experience hair loss may find that reducing their dosage allows their hair loss to abate. Lithium in particular, rarely has to be discontinued entirely.[44]https://pubmed.ncbi.nlm.nih.gov/3157663/
Understanding more about the relationship between dose and hair loss may help researchers learn more about the mechanisms behind cause and effect.
Hair loss related to psychopharmaceuticals is overwhelmingly experienced by women, not men. In one literature review, nearly 89% of the reports came from women.[45]https://pubmed.ncbi.nlm.nih.gov/16783834/ Understanding why women seem to be more affected by this type of hair loss may offer clues into the mechanism of action.
Some drugs have a multi-directional relationship to hair loss, for reasons that aren’t yet entirely understood. Valproate and valproic acid, for example, can lead to hair loss when orally administered but may lead to hair growth when applied topically. In two of the case studies mentioned above, alopecia areata improved with paroxetine treatment, a drug that has induced hair loss in others.
These multidirectional relationships may shed light on cause and effect, but also, offer insight into how complicated it is to point to any one drug as a cause of hair shedding.
Hair loss, particularly telogen effluvium, may be related to trauma, stress, anxiety, or depression. Some people may find their hair loss improves as their anxiety and depression get better. On the other hand, researchers acknowledge it’s possible that cases of hair loss are underreported, either due to self-neglect or because the patient has experienced it in the past as a result of emotional stress and does not relate the occurrence to the drug.
In general, the incidence rate for these reports of hair loss associated with antidepressants, anti-anxiety medications and mood stabilizers, appears to be quite low. It’s not a given that hair loss is an outcome with any of these drugs.
That said, hair loss can be devastating for the one person that experiences it. And in some cases, may lead to non-compliance with what otherwise are very effective and life-improving drugs.
Before deciding to forego or discontinue treatment, it’s worth it to consider that in all the cases mentioned above, patients reported their hair shedding stopped after an adjustment to dosage, or once treatment ended.
For those who have recently begun taking a new medication and have noticed hair thinning or hair shedding, it would be advisable to speak with a doctor about switching to another medication. Remember, there were several antidepressants and anti-anxiety medications that did not make the list because there was no evidence linking them to hair loss.
That said, if a medication on this list lands in the medicine cabinet, the risk of hair loss remains very low.
It’s true there are case studies linking some psychopharmaceuticals to hair loss. But generally, the incidence rates are low, and hair loss tends to stop when dosages are lowered or the use of the drug is discontinued.
That said, for the individual experiencing hair loss, it’s of little comfort to know that risk is low. Maintaining healthy hair can be an important part of maintaining emotional and psychological health. If treating anxiety or depression is having a negative effect on hair, it may be time to talk to a doctor or dermatologist about an alternative treatment plan.
While happiness and health should always supersede hair growth, in this case, people shouldn’t have to sacrifice either.
References[+]
↑1 | https://link.springer.com/article/10.2165/00002018-199410040-00005 |
---|---|
↑2, ↑3, ↑42 | https://pubmed.ncbi.nlm.nih.gov/10798824/ |
↑4 | https://www.psychiatria-danubina.com/UserDocsImages/pdf/dnb_vol33_no2/dnb_vol33_no2_187.pdf |
↑5 | https://www.psychiatrist.com/pcc/depression/escitalopram-induced-hair-loss/ |
↑6 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035805/ |
↑7 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219523/ |
↑8 | https://pubmed.ncbi.nlm.nih.gov/34355374/ |
↑9 | https://pubmed.ncbi.nlm.nih.gov/31599441/ |
↑10 | https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/hair-loss-associated-with-fluoxetine/D2A55E09DDCF393399C14DB9289BAADE |
↑11 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC514846/ |
↑12 | https://pubmed.ncbi.nlm.nih.gov/19630647/ |
↑13 | https://pubmed.ncbi.nlm.nih.gov/34181746/ |
↑14 | https://sci-hub.se/https://pubmed.ncbi.nlm.nih.gov/16922952/ |
↑15 | https://pubmed.ncbi.nlm.nih.gov/11737460/ |
↑16 | https://pubmed.ncbi.nlm.nih.gov/10883182/ |
↑17 | https://pubmed.ncbi.nlm.nih.gov/10442258/ |
↑18 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589582/ |
↑19 | https://pubmed.ncbi.nlm.nih.gov/18664165/ |
↑20, ↑45 | https://pubmed.ncbi.nlm.nih.gov/16783834/ |
↑21 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000200/ |
↑22 | https://pubmed.ncbi.nlm.nih.gov/28763345/ |
↑23 | https://sci-hub.se/https://pubmed.ncbi.nlm.nih.gov/12500769/ |
↑24 | https://pubmed.ncbi.nlm.nih.gov/17293712/ |
↑25 | https://pubmed.ncbi.nlm.nih.gov/19471188/ |
↑26 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579479/ |
↑27 | https://pubmed.ncbi.nlm.nih.gov/23525591/ |
↑28 | https://pubmed.ncbi.nlm.nih.gov/22265699/ |
↑29 | https://pubmed.ncbi.nlm.nih.gov/7995585/ |
↑30 | https://pubmed.ncbi.nlm.nih.gov/3126095/ |
↑31 | https://pubmed.ncbi.nlm.nih.gov/6519870/ |
↑32 | https://pubmed.ncbi.nlm.nih.gov/6838778/ |
↑33 | https://pubmed.ncbi.nlm.nih.gov/6404546/ |
↑34 | https://pubmed.ncbi.nlm.nih.gov/6809028/ |
↑35 | https://pubmed.ncbi.nlm.nih.gov/30193142/ |
↑36 | https://pubmed.ncbi.nlm.nih.gov/30386073/ |
↑37 | https://pubmed.ncbi.nlm.nih.gov/29061425/ |
↑38 | https://pubmed.ncbi.nlm.nih.gov/27889835/ |
↑39 | https://pubmed.ncbi.nlm.nih.gov/8899137/ |
↑40 | https://pubmed.ncbi.nlm.nih.gov/1486112/ |
↑41 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756276/ |
↑43 | https://pubmed.ncbi.nlm.nih.gov/16217127/ |
↑44 | https://pubmed.ncbi.nlm.nih.gov/3157663/ |
If you’re experiencing hair loss, and you’re searching for a solution to help regrow hair, you’ve likely read several articles that reference different parts of the scalp. But what would you say if you were asked where on your scalp you’re losing hair? And how well do you understand the various parts of the scalp that lay beneath the skin, as well as their roles in hair loss?
In this article, we’ll give a quick introduction to the scalp. After that, we’ll take a tour of the scalp, starting with the different regions on the surface; then moving beneath the skin through the various layers of scalp tissue; then exploring the bones that lay beneath the tissue; then discussing the arteries, veins, nerves, and lymph vessels than run through those layers of tissue; and then examining the muscles that pull on the scalp. After touring the different areas of the scalp, we’ll discuss some ways that scalp mechanics may impact hair growth. Finally, we’ll look at some clinical evidence that has opened up the possibility of new treatments for androgenic alopecia.
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
The scalp consists of layers of skin and subcutaneous tissue that cover the human cranium. It extends from the supraorbital foramina (i.e. two openings in the bone just above the eye sockets and just beneath the eyebrows) to the superior nuchal line (i.e. one of four curved ridges on the exterior surface of the occipital bone, which lies at the back of the head). It is bordered on the front by the face and on the sides and back by the neck.
The scalp acts as a physical barrier to protect the cranium against physical trauma and potential pathogens. It is also the area where human hair typically grows in order to 1) aid in heat conservation, and 2) play a role in aesthetic appearance and sexual signaling.
If someone were to ask you where on your scalp you’re losing hair, would you know how to answer them? If you’re unsure how to answer that question, check out the descriptions below.
The surface of your head has seven main areas, or regions, which are described below:
While the previous section provides a good overview of the various areas on the surface of the scalp, there is a lot more going on beneath the surface.
Tajran J, Gosman AA. Anatomy, Head and Neck, Scalp. [Updated 2021 Jul 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
The first three layers of the scalp are firmly attached to each other and move as a unified structure.
As noted above, the pericranium is firmly attached to the calvaria bones, which form the top of the human skull. In addition to the calvaria, there are some other cranial bones that play a role in scalp function. We discuss these bones below.
Minonzio, Claudio. (2019). A step towards aberration corrections for transcranial ultrasound – Estimation of skull thickness and speed of sound.
The neurocranium, which is pictured in the image above, consists of the upper part of the skull that surrounds the cranial cavity and contains the brain. There are eight bones that make up the neurocranium:
Although these are eight individual bones, they are joined together by various fibrous sutures.
The neurocranium can be further divided into an upper and lower part:
Because the calvaria makes up the top part of the skull, these bones are more significant when discussing hair growth/loss. However, the muscles that attach to the temporal and sphenoid bones may also play a role in hair loss (more on that in a bit).
We previously discussed the five layers of the scalp. There are also a number of arteries, veins, nerves, and lymphatic vessels that run through those layers. We discuss each of these below.
The common carotid arteries, a pair of arteries on either side of the neck, provide the main supply of blood to the scalp. While still in the neck, each of the common carotid arteries splits into an internal and external carotid artery. Each of these branches supplies blood to different areas of the scalp.
Wikipedia contributors. Ophthalmic artery. Wikipedia, The Free Encyclopedia. January 5, 2022, 11:55 UTC.
The internal carotid artery (on either side of the skull) gives rise to an ophthalmic artery, which further branches into a supratrochlear artery and a supraorbital artery. Both the supratrochlear and supraorbital arteries rise through the supraorbital foramen (i.e. an opening in the bone just above the eye socket and just beneath the eyebrow) and connect with their counterparts on the opposite side of the skull, as well as with the superficial temporal artery (also on either side of the skull), which provides most of the blood supply to the front of the scalp.
Hacking, C., Bell, D. Scalp. Reference article, Radiopaedia.org. (accessed on 12 May 2022)
The external carotid artery (on either side of the skull) branches into the following arteries:
The venous drainage of the scalp can be split into superficial and deep components.
Tajran J, Gosman AA. Anatomy, Head and Neck, Scalp. 2021 Jul 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31855392.
Rivard AB, Kortz MW, Burns B. Anatomy, Head and Neck, Internal Jugular Vein. 2021 Jul 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 30020630.
Germann AM, Jamal Z, Al Khalili Y. Anatomy, Head and Neck, Scalp Veins. 2021 Dec 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31082005.
The front and sides of the scalp are innervated by trigeminal nerves, while the back of the scalp is innervated by cervical nerves.
Wikipedia contributors. Trigeminal nerve. Wikipedia, The Free Encyclopedia. March 31, 2022, 01:23 UTC.
There are two trigeminal nerves – one on each side of the skull. Each trigeminal nerve has three major branches:
Roesch ZK, Tadi P. Anatomy, Head and Neck, Neck. 2021 Jul 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31194453.
Rivard AB, Kortz MW, Burns B. Anatomy, Head and Neck, Internal Jugular Vein. 2021 Jul 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.
The rear portions of the scalp drain lymphatic fluid through the posterior auricular lymph nodes (i.e. a small group of lymph nodes located just beneath the ear) and occipital lymph nodes (i.e. lymph nodes located at the back of the head, near the occipital bone). The posterior auricular lymph nodes drain the area of the scalp located directly behind the ear and flow into the occipital lymph nodes, while the occipital lymph nodes drain lymphatic fluid from the remaining regions in the back of the scalp.
There are a handful of muscles that act on the scalp.
Roesch ZK, Tadi P. Anatomy, Head and Neck, Neck. 2021 Jul 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31194453.
The auricular muscles are a group of muscles of the auricle (i.e. the visible portion of the ear). Although there are nine total auricular muscles on either side of the skull, six of those muscles are intrinsic muscles located deep within the skull, while the other three are extrinsic muscles that are located more superficially. It is the three extrinsic muscles that we’re concerned with for this article.
Although the auricular muscles play a minor role in fixing the position of the ear, they are considered vestigial in humans. Nevertheless, these muscles may play a role in restricting blood flow to the scalp (more on this in a bit).
The temporoparietalis muscles are a pair of muscles located just above and in front of the auricularis superior muscles on either side of the head. These muscles lie over both the temporal and occipital bones, connecting to the fascia (i.e. a thin sheath of fibrous tissue enclosing a muscle or other organ) just above the ear on one end and the galea aponeurotica on the other. The temporoparietalis muscles help to fix the galea aponeurotic and elevate the ears.
The temporalis muscles are broad, fan-shaped muscles located on either side of the head. These muscles cover most of the temporal bones and help produce movements of the mandible, or jawbone, when chewing. Although these muscles are more associated with the mandible than they are the scalp, the contraction of these muscles may restrict blood flow to the scalp, which could have an effect on hair growth/loss (more on this below).
Now that you have a better understanding of scalp anatomy, we can examine ways that scalp mechanics may impact hair growth. In particular, the galea aponeurotica and the surrounding musculature may play a role in restricting blood flow (and oxygen) to the scalp.
We know from previous studies that balding scalps tend to have 2.6 x less subcutaneous blood supply compared to non-badling controls. Moreover, several blood-pressure-lowering medications – such as minoxidil, diaoxide, and pinacidil – have been shown to improve androgenic alopecia – one of the world’s most common hair loss disorders. These findings implicate reduced blood supply as a potential contributor to pattern hair loss. And while it’s still debated just how much the reductions to blood flow are a cause or consequence of androgenic alopecia, there may be a therapeutic benefit to improving blood, oxygen, and nutrient levels to balding hair follicles.
Below, we examine the impact of scalp musculature on arterial branches, as well as the impact of the galea aponeurotica and surrounding musculature on microcirculation (i.e. capillaries in the scalp).
Dermatologists report that roughly 80% of men with androgenic alopecia tend to have “tight” scalps, suggesting that the muscles around the perimeter of the scalp have involuntarily contracted and are pinching the arterial branches, causing a reduction in blood supply. This is also supported by research measuring scalp hardness in balding versus non-balding men across a variety of scalp regions.[1]https://www.researchgate.net/publication/338624064_Androgenetic_alopecia_is_associated_with_increased_scalp_hardness
So, do the muscles surrounding the scalp perimeter and anchored to the galea aponeurotica have anything to do with these phenomena? Some evidence suggests yes.
As noted previously, the supraorbital and supratrochlear arteries are two of the three arterial branches that supply the majority of blood to the frontal region of the scalp. These arteries pass through the cranial bone at the eyebrows, run underneath the frontalis muscle, then pierce through the frontalis muscle before running upward toward the hair line. When the frontalis muscle flexes, this flexing can compress the supraorbital and supratrochlear arteries, restricting blood flow to the scalp.[2]https://academic.oup.com/asj/article-abstract/41/11/NP1599/6206455
In addition, the deep temporal artery resides between the cranium and the temporalis muscles. When these muscles contract, they can compress the deep temporal artery against the skull and constrict blood supply.
Moreover, some branches of the auricularis anterior and posterior arteries weave between the auricular muscles and their supporting tendons. It is possible that the contraction of the auricular muscles may restrict blood flow in the same manner.
Finally, while many of the scalp’s arteries reside in the fascia that overlies the scalp muscles, the contraction of the muscles underlying these arterial branches can still affect them. We know this because studies have shown that when the temporalis muscle contracts, the artery overlying it (the superficial temporal artery) constricts by 50%, thus leading to a ~75% decrease in blood supply in that arterial branch.[3]https://n.neurology.org/content/11/11/935
But that’s not the whole story.
Despite the possible restriction of arterial blood flow described in the previous section, it is generally believed that reductions to blood flow in androgenic alopecia are mainly due to the loss/restriction of the microcapillary networks (i.e., the small blood vessels supporting the hair follicles themselves), rather than reductions from the carotid arterial branches supporting those microcapillary networks.
The microcapillary networks may constrict or compress as a result of mechanical stretch across the galea aponeurotica (mediated by the contraction of the scalp’s perimeter muscles). Because the top of the scalp is a fixed area, stretching of the galea aponeurotica would generate compression of the underlying microcapillary networks supplying hair follicles.
We see hypoxia (i.e. insufficient supply of oxygen) as a trigger of hair loss in mouse models, but is it relevant to humans with androgenic alopecia? Unfortunately, we still don’t know (since there are also reductions to blood supply resulting from the hair follicle miniaturization that follows each re-entry into the anagen stage of the hair cycle).
Interestingly, there used to be a surgery called “scalp reduction,” where surgeons would place a balloon underneath the galea aponeurotica, slowly inflate it over a series of weeks, and then give patients a surgery to “remove” bald regions and pull the hair-bearing stretched skin over to create the appearance of a fuller head of hair. In the 1990s, these surgeries were quietly abandoned after surgeons started voicing concerns of accelerated hair loss in patients following the procedure. Was this accelerated hair loss caused by skin tension? Did this tension lead to microcapillary compression? We still don’t know the answers, but the questions certainly are interesting.
Despite the lack of certainty regarding the impact of blood flow (and oxygen) on androgenic alopecia, the results from a number of Botox studies show that when the muscles surrounding the scalp are forcibly relaxed in patients with androgenic alopecia, hair growth/loss improves.
Botulinum toxin, which is commonly referred to by the brand name Botox, is an injectable neuro modifier that’s used as a therapeutic treatment for many clinical and cosmetic concerns. Specifically, Botox is used to help relax muscles and reduce certain inflammatory signaling proteins.
Over the last decade, there have been five clinical studies published on the hair-promoting effects of Botox on men with androgenic alopecia. Four of those studies tested intramuscular Botox injections (i.e. injections directly into the scalp’s perimeter muscles), while the fifth study tested intradermal Botox injections (i.e. injections directly into balding regions of the scalp). We examine the results from both types of studies below.
Across the four studies testing intramuscular Botox injections, 75-80% of participants responded favorably (i.e. hair growth) with an average hair count increase of 18-21% after 6 to 10 months. Injections into the scalp perimeter muscles were done once every 4-6 months, with results becoming cosmetically significant after the second round of injections.
In addition to testing the use of Botox injections on their own, one of the four studies also examined using Botox injections alongside oral finasteride (i.e. the active ingredient in Propecia). This combined therapeutic approach led to improved response rates and hair count increases that average nearly 35%.
Researchers suspect that two mechanisms contributed to these results:
Despite researcher’s suspicions, it’s important to note that these suggested mechanisms are only speculative at this point. We will need more data in order to corroborate these suspicions.
In the one study that tested intradermal Botox injections, 60-80% of participants responded favorably (i.e. hair growth) with an average hair count increase of 5% after 6 months. Injections into balding regions were done every four weeks.
Although this study’s response rate is similar to the intramuscular studies above, the hair count increases were much lower. It’s worth noting that these results might improve with higher-dose injections. This study used just 30 units of Botox, spread across the entire scalp. When another investigator increased the amount of Botox injected from 30 units to 100 units, and also doubled the frequency of injections, they observed more significant hair growth.[4]https://www.dovepress.com/getfile.php?fileID=73853
While conducting the study of intradermal Botox injections, researchers also conducted a cell culture on human hair follicles. They found that Botox appears to decrease the expression of transforming growth factor beta 1 (TGFB-1), a signaling protein that acts as a negative regulator of the hair cycle. TGFB-1 also appears to be intimately tied to hair follicle miniaturization, causing researchers to speculate that intradermal Botox injections might be down regulating TGFB-1 in human hair follicle sites, and in doing so, allowing for hair loss improvements.
It’s important to note that the reduction of TGFB-1 happens in a dose- and time-dependent manner. Given this fact, it makes sense that increasing both the volume and frequency of intradermal injections evokes a more robust improvement in hair count.
As with the intramuscular studies above, it’s important to note that the suspected mechanism (i.e. the down regulating of TGFB-1) identified in the intradermal study is only speculative. In order to corroborate this suspicion, more data will need to be collected.
Although the results from the Botox studies look promising, the amount of evidence on Botox as a treatment for androgenic alopecia is still rather small. And while several research groups have found consistent results, these studies tend to score lower on the hierarchy of evidence. So, we should interpret those results with caution.
There are at least three significant issues with the Botox studies:
In addition to the above three issues, it’s also worth noting that 1) there are currently no established best practices for the use of Botox to treat androgenic alopecia, and 2) Botox treatment can be rather expensive, with intramuscular injections costing $2,400 to $4,000 per year and intradermal injections running $4,800 to $12,000 per year.
This isn’t to say we should dismiss the evidence in favor of using Botox to treat androgenic alopecia. At the same time, it’s important not to jump to any conclusions regarding the efficacy of using Botox versus other treatment options.
In this article, we’ve shown how the scalp has a rather complex anatomy – including seven regions on the surface of the scalp; five tissue layers; several bones that the scalp attaches to; a number of arteries, veins, nerves, and lymphatic vessels running through the scalp; and a collection of muscles that pull on the scalp. We’ve also discussed ways that scalp mechanics may impact hair growth, and reviewed five studies that suggest Botox injections may improve hair loss by relaxing the muscles around the perimeter of the scalp.
Although the findings from Botox studies are still preliminary, they have opened up the possibility of new treatment targets for androgenic alopecia. Any relevant treatment targets would need to relax the muscles around the scalp so that 1) arterial branches can deliver an adequate supply of blood (and oxygen) to the scalp, and 2) tension in the galea aponeurotica doesn’t restrict blood flow in the microcapillary networks that feed hair follicles.
In addition to the results from the Botox studies, there’s mechanistic research to suggest that skin tension in balding regions (generated from the contraction of muscles around the scalp) might have something to do with the arrival of dihydrotestosterone (DHT) and the balding process itself.[5]https://www.sciencedirect.com/science/article/pii/S0306987717310411
Finally, it’s worth noting that Botox injections are not the only way to relax the muscles around the scalp. Scalp massages may offer a viable, less-expensive method for treating androgenic alopecia that targets the same mechanisms as Botox injections.
References[+]
↑1 | https://www.researchgate.net/publication/338624064_Androgenetic_alopecia_is_associated_with_increased_scalp_hardness |
---|---|
↑2 | https://academic.oup.com/asj/article-abstract/41/11/NP1599/6206455 |
↑3 | https://n.neurology.org/content/11/11/935 |
↑4 | https://www.dovepress.com/getfile.php?fileID=73853 |
↑5 | https://www.sciencedirect.com/science/article/pii/S0306987717310411 |
Our hair follicles are part of a niche of cells intimately involved in proper immune function. For example, right next to the dermal papilla, the type of cell that grows our hairs, there are a number of immune cells including:
Chen, Chih-Lung & Huang, Wen-Yen & Wang, Eddy & Tai, Kang-Yu & Lin, Sung-Jan. (2020). Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche dysfunction for hair regeneration. Journal of Biomedical Science. 27.
Mast cells can become counterproductive though when too much histamine is secreted. They induce immunoglobulin secretion by our B-cells (those same cells that act as antibodies to viruses), such as the release of IgE – the same immunoglobulin that can create anaphylactic shock.
Histamine is also a pro-inflammatory cytokine (a signaling molecule), that can generate a number of unwanted cell responses that tend to progress hair loss.
In this article, we take a look to see just how much are mast cells and histamine to blame for hair loss, and what can be done about this. We also take a look at the evidence for the use of antihistamines as a hair loss reversal tool.
Support your hair with full-strength topical cetirizine, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Histamine is counterintuitively not a hormone, instead, it’s actually a simple amino acid. We get histamine thanks to consuming its precursor amino acid histidine. And it is vitally important for maintaining normal physiology.
Histamine also binds to four receptors. Some of which are located on our skin, some in our gastrointestinal system, and some in our brain. Histamine in the brain is also important for acting as a neurotransmitter.
It’s the excess of histamine signaling that becomes problematic.
A perfect example of excessive histamine signaling being bad is in the case of seasonal allergies, or food allergies. Anyone who has had experience will know how quickly and fiery the body responds to these allergens. This is all due to the release of histamine and how it interacts with those receptors.
With excess histamine signaling, people become easily irritated and prone to inflammation. Body temperature also increases and the vascular system becomes more permeable, causing immune cells to leak into unwanted places.
This opening of our vascular system and leaking of immune cells in unwanted places is actually one way histamine connects to hair loss.
Because hair follicles and scalp act as a breeding ground for a variety of microorganisms, it is also very prone to exacerbated histamine signaling if the scalp biome balance is thrown off. Further, because histamine responds to changes in hormone levels, it’s very possible that the shift experienced with androgenic alopecia also increases histamine production.
Both androgenic alopecia and alopecia areata also show signs of dysregulated histamine signaling. Histamine in excess can induce pro-inflammatory cascades that cause premature apoptosis of cells, especially as it relates to the dermal papilla.
This rapid apoptosis can extend to cells (such as stem cells) sitting on our epidermis. Stem cells in the subcutaneous tissue and on the hair follicle’s outer root can bulge. Premature apoptosis of these cells makes it increasingly difficult to regrow hair since the stem cells which contribute to hair renewal are no longer present.
While the discussion on histamine specifically is rather sparse in relation to hair loss, there have been some advances in the past years on the role of histamine overall. For example …
Tryptase is an enzyme involved in the degradation of proteins, specifically by removing lysine, histidine, and arginine. Higher tryptase is also a hallmark of mast cell activation.
Grace SA, Sutton AM, Abraham N, Armbrecht ES, Vidal CI. Presence of Mast Cells and Mast Cell Degranulation in Scalp Biopsies of Telogen Effluvium. Int J Trichology. 2017;9(1):25-29
When the hair follicles experience a collapse of immune privilege, they also experience a dramatic increase in a variety of immunological factors. Specifically, a rise in lymphocytes like CD8+ T-cells, and IgE. Both of which are either triggers/ secrete (T-cells) histamine or can be triggered by histamine release from mast cells.
Specifically, the deep perivascular and perifollicular regions of those with alopecia areata, when compared to controls, had higher CD4+ T cell count, and CD8+ T cell count. They also had more mast cells.
Zhang X, Zhao Y, Ye Y, Li S, Qi S, Yang Y, Cao H, Yang J, Zhang X. Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata. Arch Dermatol Res. 2015 May;307(4):319-31. doi: 10.1007/s00403-015-1539-1. Epub 2015 Feb 1. PMID: 25638328.
These findings reached multiple orders of magnitude in terms of significance. Interestingly, this was not really something of concern when it came to the upper dermal region. Indicating that unless we look further down the dermis, we are unlikely to see any noticeable changes in immune profiles.
It’s not as if the androgen and the androgen receptor are initiating hair loss. Instead, the androgen receptor with DHT translocates into our cell’s nucleus and then tells the cell to change genetic expression. Some of those genes (but not all), happen to be genes for the production of extracellular matrix.
This can lead to the overproduction of elastin, leading to a feeling of hard tissue often referred to as fibrosis of the scalp. In another case-control study, the increase in collagen fibers, elastin, and the lower diameter of hair follicles, was apparently clear in those with androgenic alopecia.[2]https://pubmed.ncbi.nlm.nih.gov/18286292/
Won CH, Kwon OS, Kim YK, Kang YJ, Kim BJ, Choi CW, Eun HC, Cho KH. Dermal fibrosis in male pattern hair loss: a suggestive implication of mast cells. Arch Dermatol Res. 2008 Mar;300(3):147-52. doi: 10.1007/s00403-007-0826-x. Epub 2008 Feb 20. PMID: 18286292.
Figure (a) and the graph to the right of it are indicating the increase of collagen bundles in the occiput and vertex of either controls or those with AGA. While the occiput didn’t differ much, the vertex was clearly different.
Figure (b) is indicating the increase in elastin seen in those with androgenic alopecia as compared to control.
And when it came to mast cells, those with androgenic alopecia also had a higher level of the enzyme tryptase (again indicative of mast cell activation). Interestingly, tryptase is also a well known factor involved in the activation of TGF-ß and collagen remodeling, potentially pointing to a role of mast cells in the fibrosis of those with AGA.
Won CH, Kwon OS, Kim YK, Kang YJ, Kim BJ, Choi CW, Eun HC, Cho KH. Dermal fibrosis in male pattern hair loss: a suggestive implication of mast cells. Arch Dermatol Res. 2008 Mar;300(3):147-52. doi: 10.1007/s00403-007-0826-x. Epub 2008 Feb 20. PMID: 18286292.
It’s important to keep in mind that these findings were for a total of 10 patients and 5 controls. A greater sample size range is required to definitively tell if this is either a correlation or a fluke.
Interestingly, the increase in TGF-ß signaling appears to be contradictory when it comes to alopecia areata. In androgenic alopecia it’s implicated as a fibrosis-inducing agent, while in alopecia areata, the loss of TGF-ß is a precursor step to loss of immune privilege.
This change in activity of TGF-ß is known to be induced by a shift in mast cells from an immune-inhibitory role to a pro-inflammatory role.[3]https://pubmed.ncbi.nlm.nih.gov/24832234/
One research group had actually investigated this separately with a mice model and determined with incredible accuracy that one of the reasons for the differential response of mast cells as either good or bad, is partly due to the scalp microbiome and dermal fibroblasts.[4]https://pubmed.ncbi.nlm.nih.gov/30928651/
The mice study showed that the scalp microbiome activates toll-like receptors (a type of immune recognition receptor) and amplifies progenitor cells from the keratinocyte to become mast cells. Further, a change in how the mast cells behaved was seen. One of immune inhibition into one of pro-inflammation and immune cell recruitment.
It’s possible that for alopecia areata, a change in how the scalp microbiome interacts with immune cells is the prelude to the disease. While with androgenic alopecia, a change in how mast cells behave is a prelude to premature apoptosis of the dermal papilla cells.
The next step in assessing the role of mast cells in hair loss is to consider if anyone has looked at the use of antihistamines for hair loss. After all, while mechanistic and observational data connecting histamines to hair loss are important, interventional studies are really the only way to ascertain cause and effect.
Luckily, there are some research papers that addressed this question.
The first study investigated the antihistamine drug cetirizine (if you’ve ever tried claritin or zyrtec, this is the same active ingredient), because of its known inhibitory actions on histamine-1 receptors and PGD2 (a proinflammatory prostaglandin shown to worsen androgenic alopecia).[5]https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.13940
What the authors did was give 30 participants a 1% solution of topical cetirizine at 1mL doses. The second group which served as a control group was given a placebo solution. After six months these were the results:
Zaky, M. S., Abo Khodeir, H., Ahmed, H., & Elsaie, M. L. (2021). Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case‐controlled study. Journal of Cosmetic Dermatology, 20(4), 1154–1159.
Essentially, the control group showed no improvement with 4/30 of them seeing worsening responses. While the treatment group saw sparse improvements in photographic assessments and self assessments. Nothing too crazy, but still better than the control group.
In a second study, researchers compared 1% cetirizine vs. 5% minoxidil. In this randomized controlled trial, both groups saw great results in terms of hair density, hair diameter and other hair loss parameters. Minoxidil however, outperformed topical cetirizine.[6]https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31456/21623
This is expected since minoxidil works by promoting the anagen phase of hair follicles. Cetirizine simply works by blocking the uptake of histamine in the histamine-1 receptor. This is fascinating to note though as by simply blocking the cellular actions of histamine, cetirizine has comparability to minoxidil.
Hossein Mostafa, D., Samadi, A., Niknam, S., Nasrollahi, S. A., Guishard, A., & Firooz, A. (2021). Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. Journal of Pharmacy & Pharmaceutical Sciences, 24, 191–199.
Their outcomes showed some of the following features:
Nonetheless, a combined therapy may be even more potent at addressing hair loss…
In the final study on cetirizine, patients were once again administering 1mL of a 1% solution of cetirizine topically. After six months, a dramatic improvement in hair regrowth was seen for the participants when compared to the control group.[7]https://pubmed.ncbi.nlm.nih.gov/28604133/
Rossi, A., Campo, D., Fortuna, M. C., Garelli, V., Pranteda, G., De Vita, G., … Carlesimo, M. (2017). A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. Journal of Dermatological Treatment, 29(2), 149–151.
The top row indicates the beginning of the study for the participants. While the bottom row indicates the end of the study. A clinical difference can be seen in all of the patients’ hairlines. In all cases, there were no known side effects too.
There is a clear rationale for the induction of mast cells in the pathology of possibly all forms of hair loss, including a connection to immune defects like telogen effluvium. Mast cells play a critical role in feedback from the scalp microbiome to our scalp cell niche.
When mast cells go awry, they release histamine, tryptase, and a number of other factors that cause extracellular matrix remodeling, recruitment of immune cells, and a vicious cycle progressively worsening with time.
Addressing the excess histamine production by interfering with the histamine-1 receptor with cetirizine, abrogates most of the negatively associated responses and actually does seem to allow regeneration of hair follicles.
The use of topical cetirizine can be a very appropriate tool to implement with androgenic alopecia and alopecia areata. The rise of mast cells and the enzyme tryptase in patients with telogen effluvium as compared to controls also provides a very compelling argument as to how stress correlates with hair shedding disorders.
It is with the totality of the current evidence, prior knowledge on the mechanisms of mast cells and their roles in our bodies, as well as the efficacy of antihistamines in improving hair loss, that we believe the weight of the evidence largely supports a causal role of mast cells in the development of various forms of hair loss.
Since topical cetirizine consistently shows a net benefit in all the current clinical trials, the most logical addition should be topical cetirizine for any hair loss disorder. It may be that in conjunction with minoxidil, large improvements can be acquired.
Further, with topical anti-inflammatories, cetirizine can dramatically reduce the apoptosis rate of precious stem cells surrounding our hair follicles. There are alternatives to cetirizine that operate in similar mechanisms, reducing histamine release and subsequent binding to histamine-1 receptors.
Some of the useful ingredients that can reduce histamine production and the effects of histamine include:
And many more. A majority of the micronutrients and vitamins are also key cofactors for proper function of the enzymes involved in histamine degradation – such as Diamine oxidase and Histamine-N-Methyl Transferase enzymes.
Although we can’t generally acquire topical cetirizine, one can be made by dissolving 1 g in 100mL of water. Forming 1% w/v cetirizine, just as outlined in the studies. The only difference would be that the study used a form of alcohol instead of water.
A simple formulation you can make at home includes:
*Note: If you plan on using oral antihistamines, remember that they distribute widely throughout the body, not just the skin. The compounds prevent histamine from binding to the brain which is one of the reasons for the drowsy feeling many experience with Zyrtec or Claritin.
References[+]
↑1 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514792/ |
---|---|
↑2 | https://pubmed.ncbi.nlm.nih.gov/18286292/ |
↑3 | https://pubmed.ncbi.nlm.nih.gov/24832234/ |
↑4 | https://pubmed.ncbi.nlm.nih.gov/30928651/ |
↑5 | https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.13940 |
↑6 | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31456/21623 |
↑7 | https://pubmed.ncbi.nlm.nih.gov/28604133/ |
Subscription services have gained popularity in recent years for all types of products, from home cleaning supplies to underwear, razors, and even toothpaste. These services make the most sense for products used consistently, saving the consumer time and money. Hair regrowth treatments certainly meet the criteria. For the most part, they only work as long as you keep using them. So, it was only a matter of time before startups put men’s hair care on autopay.
Of the telemedicine providers focusing on men’s health, Hims, Keeps and Roman have risen to the top of this competitive market. But which one is best? We offer an objective side-by-side comparison of these 3 hair loss subscription companies. In the process, you’ll learn about the following:
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
Hims, Keeps, and Roman all offer the same hair regrowth products, namely Finasteride and Minoxidil. These are the only two medications approved by the FDA to treat androgenic alopecia (AGA), or male pattern baldness.
Finasteride, also known by the brand name Propecia, is one of the most well studied, and most powerful, drug for AGA. The daily pill stops the progression of hair loss in 80-90% of men and, on average, leads to a 10% increase in hair count over two years.[1]https://www.sciencedirect.com/science/article/pii/S0022202X15529357
Oral finasteride is an FDA-approved treatment for AGA that inhibits the enzyme type II 5-alpha reductase, and thereby reduces dihydrotestosterone (DHT) levels in the body. While it’s effective in slowing, stopping, and partially reversing AGA’s progression, some men can experience side effects associated with the systemic reduction in DHT levels.
Topical Finasteride aims to avoid such side effects by localizing the drug’s effects to the scalp. Research on topical finasteride is still in its infancy, but the drug does appear to be effective for lowering DHT in the scalp. Real world results vary widely in part because method of delivery, dilution ratios and carrier agents (non-active ingredients) used to deliver the drug, also vary widely.
Minoxidil, also known by the brand name Rogain, is the other FDA-approved drug for the treatment of AGA. Although available orally, it’s most popular as a topical. Over half of those who try topical minoxidil respond to the drug within 3-6 months. Of those, research reports hair count increases of up to 12% over 48 weeks.[2]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691938/
Among the downsides of Minoxidil is that the treatment’s effectiveness does wane over time. When that happens, those who quit tend to lose any and all gains they had from the drug, ending up back where they started before ever having used it.
One reason why Minoxidil’s effectiveness might taper is that it doesn’t address hair follicle miniaturization. So, while it does increase hair counts by kicking hair back into the growth cycle, hair continues to thin over time.
When combined with additional therapies, however, most if not all of these downsides can be mitigated. Minoxidil may work better when combined with scalp exfoliators such as retinol or retinoic acid. Research also finds minoxidil is up to four times more effective when combined with microneedling.[3]http://www.ijtrichology.com/article.asp?issn=0974-7753;year=2013;volume=5;issue=1;spage=6;epage=11;aulast=Dhurat
The effectiveness of Minoxidil may be best when used with Finasteride. These two treatment options can be combined.
Both Finasteride and Minoxidil require ongoing, daily application for results maintenance. Hence, the appeal of subscription services. So let’s take a closer look at the three biggest players offering Finasteride and Minoxidil online.
Hims, Keeps and Roman are telemedicine providers who, after a phone or video consultation, provide prescriptions for hair loss treatments. Products are shipped discreetly to the buyer’s home, with savings available for ongoing, subscription-based delivery.
Hims brands themselves as ‘all about personal wellness.’ The company offers products not only for hair loss, but also for men’s sexual health. They sell both prescription-based and over-the-counter solutions.
Roman is the men’s health wing of Ro.co, a consumer healthcare company with a mission to make healthcare accessible and convenient. The digital healthcare provider wants to make it easier for more men to seek preventative care. Of these 3 companies, they treat the widest range of men’s health conditions.
Keeps focuses only on treating hair loss, versus general men’s health. Founded in 2018, the company aims to ‘help more men keep more hair.’ In addition to selling prescription treatments and hair care products, Keeps will link clients to hair restoration surgeons.
Each of the above companies sells generic Finasteride and Minoxidil, but the products differ slightly between sites. Below is a closer look at what’s on offer.
Of the 3 providers, Hims sells the greatest variety of products and hair treatment packages. The Hair Power Pack includes a combination of oral finasteride and 5% Minoxidil, plus Biotin gummies and a thickening shampoo.
Hims is also the only of the three companies to offer a topical Finasteride. The topical combines 0.3% finasteride with 6% Minoxidil. Active ingredients are diluted in alcohol (ethanol), propylene glycol and citric acid and delivered via spray bottle.
Propylene glycol as a carrier does lead to skin irritation in up to 6% of users, although this is considered a very mild side effect.[4]https://pubchem.ncbi.nlm.nih.gov/compound/Propylene-glycol
Keeps does not offer a topical finasteride, but does include options for either foam or serum-based Minoxidil just as Hims does. They are also the only provider to sell a 2% ketoconazole shampoo. Alongside finasteride and minoxidil, ketoconazole is considered one of the “big three” treatment options for pattern hair loss.
Despite its popularity, however, ketoconazole is not actually FDA-approved for pattern hair loss, nor is it as well-researched as minoxidil or finasteride. However, the low-cost, low-effort treatment (used 2-3 times per week) seems to carry little (if any) risk of side effects.
Roman is the biggest generalist of the companies we’re comparing here. Hair loss is not necessarily their primary focus and they have the least number of hair-related products on offer. Roman offers oral finasteride, a Propecia generic made by Ascend in India, as well as a solution-based Minoxidil made by Pure Source, LLC. They do not offer a foam-based Minoxidil as Hims and Keeps do.
Topical minoxidil is an over-the-counter product and can be purchased directly without a telemedicine consult. Finasteride, whether oral or topical, and 2% ketoconazole do, however, require a prescription. How this process works differs slightly between Roman, Hims and Keeps.
Hims begins with a free online consultation that includes a few personal questions, and offers quick access to a licensed medical provider, in all 50 states. Subscribed medications are then filled at a licensed pharmacy, and shipped to you directly.
Shipping info and billing frequency??
Keeps also begins with a free online consultation. After answering a few questions online, Keeps requires an upload of photos, which are then reviewed by a licensed provider. Treatments are shipped every 3, 6 or 12 months. Continued on-demand access to a live medical professional is available via their app for $10/month.
Like the rest, Roman’s process begins with a free online visit. Depending on the state, a phone or video chat with a doctor or nurse practitioner may be required. Prescriptions are filled via the Ro Pharmacy Network, and shipped directly in discreet packaging. Roman offers free, unlimited follow-ups if needed. Prescriptions are available in monthly or quarterly auto-shipments.
Whether Roman, Hims, or Keeps is best is a personal decision that depends on the treatment sought, any extra over-the-counter shampoos, vitamins or other add-ons desired, and what state the patient lives in.
Of the three companies in our comparison, Hims offers the most treatment options and is the only one to offer topical finasteride. Topical finasteride is also available from the following, lesser known companies:
On the other hand, Hims also ranks as the most expensive for either Finasteride or Minoxidil.
Keeps is the only provider on our list to offer Ketoconazole shampoo. So for those interested in trying the ‘Big 3’ protocol for hair loss, Keeps is a good bet. It’s also the least expensive provider of Finasteride and Minoxidil.
The main drawback of Keeps is that it’s not yet available in every state. They can, however, fill prescriptions in every state. So if you have a prescription from another doctor, Keeps may be able to fill it for a lower price.
Of these 3 digital medicine providers, Roman is doing its best to position itself as a one-stop-shop for all things health-related. Contact with a licensed healthcare professional is available in every state, and you can go to Roman for nearly all things health-related.
The downside is that Roman is not focused on hair loss prevention nor hair regrowth alone, and they offer the most limited treatments options out of the 3 on our list.
Roman, Hims, and Keeps are all telemedicine providers who have risen to the top of the competitive men’s wellness market in part due to their focus on hair loss prevention and treatment.
Each company focuses primarily on oral finasteride and topical (OTC) minoxidil and will prescribe the former after a brief online consultation.
Subscription services and products vary. Which is best may depend on the state the patient lives in, and exactly which treatments are being sought.
References[+]
↑1 | https://www.sciencedirect.com/science/article/pii/S0022202X15529357 |
---|---|
↑2 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691938/ |
↑3 | http://www.ijtrichology.com/article.asp?issn=0974-7753;year=2013;volume=5;issue=1;spage=6;epage=11;aulast=Dhurat |
↑4 | https://pubchem.ncbi.nlm.nih.gov/compound/Propylene-glycol |
To some extent, every hairline is unique. But there are identifiable hairline patterns, primarily based on age, gender and genetics. As men age, their hairline will typically recede a bit, known as ‘maturing.’ While this can understandably make men nervous, it’s not always a sign of male pattern balding. In this post, we’ll review the following:
Low-dose & full-strength finasteride available, if prescribed*
Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.
*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.
The hairline is the boundary between hair follicles and the forehead. Everyone’s hairline is unique, although there are some patterns that occur throughout our lives.
According to observational studies, prepubescent men and women both experience concave shaped hairlines. This generally concave hairline is similar across all races and ethnicities. Around the age of 10, a small percentage of children develop a widow’s peak, but this is not an effect of recession at the temples.[1]https://www.researchgate.net/publication/256479799_Phenotype_of_Normal_Hairline_Maturation
Full citation: Rassman, William & Pak, Jae & Kim, Jino. (2013). Phenotype of Normal Hairline Maturation. Facial plastic surgery clinics of North America. 21. 317-24. 10.1016/j.fsc.2013.04.001.
As young teens, when hair is fullest, there’s typically a stark boundary between the hair on the head and the forehead. In men especially, this changes with age. It’s believed that hormonal changes trigger the expression of certain genes, causing men’s hairlines to mature between mid-adolescence and middle-age. This maturation means the hairline shifts a few centimeters further back on the forehead.
This shift may take place uniformly, following the rounded shape of the juvenile hairline, or may be more noticeable at the temples, resulting in a hairline that looks more like a letter M. There appears to be a relationship between the muscles of the forehead, the frontalis muscle, and the height of the hairline. Most adults with high mature hairlines have presented with high foreheads their entire lives. The varying degrees of normal hairline maturation can be seen in the image below.
Full citation: Rassman, William & Pak, Jae & Kim, Jino. (2013). Phenotype of Normal Hairline Maturation. Facial plastic surgery clinics of North America. 21. 317-24. 10.1016/j.fsc.2013.04.001.
As hairlines mature with age, some men hardly notice this change, as it occurs slowly over a period of 10 years or more. In others, this change happens more rapidly, causing concern.
Regardless of when or how quickly it happens, what characterizes a mature hairline is that the recession is limited to just a few centimeters, and then it stops. The hairline does not continue to recede, and remains well-defined, with little to no hair thinning.
A maturing hairline is a natural part of aging, and not indicative of androgenic alopecia (AGA), otherwise known as male pattern baldness.
If and when a juvenile hairline begins to recede, the most commonly asked question is – when does it typically stop?
Just as there’s no telling if and when the hairline will mature, there’s no predicting when a mature hairline will stop. A slightly different, but better question is – how do you differentiate between a maturing hairline, which will eventually stop receding, and receding hairline, which is a sign of male pattern baldness?
To answer this, we begin with an understanding of receding hairlines.
Bypass years of trial and error. Get a personalized Regrowth Roadmap tailored to your hair loss type and treatment preferences. And leverage our support to implement it effectively.
A receding hairline is among the earliest signs of androgenic alopecia. AGA often follows a predictable pattern. This pattern begins with a receding hairline, which is especially noticeable at the temples. Simultaneously or sequentially, hair then disappears from the crown of the head. Eventually, complete baldness occurs as the hairline recedes far enough back, and/or baldness from the crown of the head meets the hairline.
The Norwood-Hamilton scale is used by dermatologists to assess progression of AGA. By stage 2, minor recession of the hairline exists, although it’s barely differentiated from a maturing hairline. By stage 3, the hairline has receded much further at the temples, characteristic of androgenic alopecia.
Hair shedding is a common part of the normal hair growth cycle. Most people lose somewhere between 50-100 hairs each day, which typically goes unnoticed. When hair loss is localized to the front of the scalp and regrowth does not occur, the hairline recedes.
Age, genetics, gender, hormones, or how you care for and style your hair can all contribute to a receding hairline.
Age: While AGA can occur in children, it’s very rare. Most of the hairline changes that occur with age are not reflective of AGA, until after the age of 17. As we age, the chances of developing a receding hairline increase. Androgenic alopecia is more common in those who are middle-aged or older.
Genetics: Research suggests that there is no single gene involved in AGA. Rather, pattern hair loss is likely a polygenic disorder, meaning there are many gene variances that are involved in the predisposition of its development. Exactly which genes are responsible is still unknown, although a family history of androgenic alopecia is still its single greatest predictor.
Gender: Men are more likely than women to have a receding hairline. Although women do experience AGA, it more often presents as overall hair thinning and baldness that begins at the top of the scalp, and not a receding hairline.
Hormones: While the hormone dihydrotestosterone (DHT), is responsible for growth of hair on the body, this testosterone derivative also contributes to hair follicle miniaturization, and ultimately, hair loss. Although it’s unknown why AGA forms the pattern it does, the answer might have to do with androgen receptor density and 5α-reductase activity at the hairline.
Lifestyle: The onset of a receding hairline may be accelerated from certain forms of stress, medications, scalp environment, and/or hair styling — such as pulling hair too tight. Hair loss may arise from hormonal conditions unrelated to DHT, such as hypothyroidism or hyperthyroidism. Gut dysbiosis, heavy metal toxicity, and vitamin deficiency can all contribute to hair loss.
Unlike maturing hairlines, receding hairlines are not part of the normal aging process, but a sign of androgenic alopecia, another form of hair loss, or both.
A mature hairline doesn’t always become a receding hairline. So what indicates the difference between the two, and how can we tell the difference between early AGA and a simple shift in the hairline?
Timing of Hair Loss: Hairlines tend to mature in late adolescence or early adulthood. Generally, receding hairlines start later in life.
Pace of Hair Loss: A receding hairline tends to progress at a faster pace. While a maturing hairline may go unnoticed – a receding hairline is more likely to attract attention.
Shape of Hair Loss: A receding hairline tends to move more towards an M-shape, with hair loss at the temples far more pronounced. A mature hairline, on the other hand, will move back more evenly.
Extent of Hair Loss: As the hairline matures, it may move back 1-2 centimeters. With a receding hairline, this shift can be 1 inch or more.
Thinning of Hair: As a hairline matures, hair maintains its original thickness. Receding hairlines, on the other hand, are accompanied by hair thinning.
A receding hairline is characteristic of androgenic alopecia, but it’s possible to have more than one type of hair loss, especially if the hairline is receding and hair is thinning or balding in other areas.
In the shower, when washing your hair, take all the hairs you shed onto your hands and stick them to the wall using the steam from the shower.
A doctor or dermatologist can help identify exactly which type of hair loss is present. This is important, for treatment protocols will vary depending on the cause of hair loss.
There isn’t one single solution for hair loss, which makes diagnosing the cause and type of hair loss important. But in general, a comprehensive solution will address the following:
Of course, no treatment is always an option. Many choose to change hair styles in an effort to hide a receding hairline, or are comfortable living with it as is. If choosing treatment, factors to consider include how much time and money to invest on hair regrowth, tolerance for side-effects, and personal preference.
A few possible interventions are listed below (and not in order of importance or clinical efficacy).
Massaging: Massaging the scalp for 15 minutes, twice daily has the ability to activate the body’s innate healing responses, and reduce scalp tension. Our own study showed that 75% of people who massaged consistently for 8 months reported a stop or partial reversal in their hair thinning.[2]https://link.springer.com/article/10.1007/s13555-019-0281-6
English, R.S., Barazesh, J.M. Self-Assessments of Standardized Scalp Massages for Androgenic Alopecia: Survey Results. Dermatol Ther (Heidelb) 9, 167–178 (2019).
Shampoos: Ketoconazole shampoo is not actually FDA-approved for pattern hair loss, but is a popular treatment for the condition nonetheless. It’s not yet very well studied, but may work well in combination with other therapies.
Natural Topicals: Jojoba, castor, rosemary, peppermint, and saw palmetto extract are just a few of the natural essential oils that have been marketed for hair regrowth. There are a few small studies showing that natural topicals may improve certain hair loss disorders.
Microneedling: Microneedling the scalp to treat hair loss is typically done biweekly. Microneedling evokes very low levels of inflammation which evoke a healing response from the body. Studies show microneedling can be successful when done alone, or when performed alongside other therapies. [3]https://www.tandfonline.com/doi/abs/10.1080/14764172.2017.1376094?journalCode=ijcl20
Semsarzadeh N, Khetarpal S. Platelet-Rich Plasma and Stem Cells for Hair Growth: A Review of the Literature. Aesthet Surg J. 2020 Mar 23;40(4):NP177-NP188.
Low-Level Laser Therapy: Low-level laser therapy (LLLT) is perhaps the most popular non-drug hair loss treatment and has FDA-clearance as a hair loss treatment for both men and women. The expensive and time consuming treatment does improve hair count for those with AGA.
Medications: Minoxidil and Finasteride are the only 2 FDA-approved medications for hair loss. Each treats AGA either orally or topically. While these medications have been proven effective to treat hair loss, they’re not for everyone. Both lead to side effects in some people, and generally require life-long use.
Botox: Botox is a neuromodulator which relaxes muscles and may also reduce certain inflammatory signaling proteins. Over the last decade, a few studies have been published measuring the hair-promoting effects of Botox on men with AGA.
Platelet-Rich-Plasma Therapy: Platelet-rich plasma therapy (PRP) is offered by thousands of dermatologists as a natural intervention for all types of hair loss. It is effective for androgenic alopecia and alopecia areata, but also expensive and ongoing injections are required to maintain results.
Stem Cell Therapy: Stem cell therapy is an expensive; relatively new therapy that is still under investigation. It’s also not a one-and-done treatment and requires multiple appointments. Early findings seem to suggest that 90% of subjects respond to stem cell therapy. And for AGA subjects, increases in hair count seem to hover around 20-30%.[4]https://pubmed.ncbi.nlm.nih.gov/31111157/
Effective treatment protocols often include some combination of the above. For example, studies suggest microneedling + minoxidil + finasteride, offers a response rate of 80-90% – with hair count increases ranging from 25-40% within 6-24 months.
As a man’s hairline matures, it will recede slightly from its juvenile position. This can be alarming, but it’s not always an early sign of male pattern baldness.
A receding hairline differs from a maturing hairline in that it may recede at a much faster pace, recede further back, and will recede more at the temples than in the center, resulting in an M-shaped hairline.
A receding hairline is characteristic of androgenic alopecia, but could be related to other types of hair loss too, especially if hair is thinning or balding in other areas.
Diagnosing a receding (vs maturing) hairline allows treatment to begin before baldness further progresses. Treatment options which have been proven effective include massaging, microneedling and medications. Efficacy improves when these methods are combined.
References[+]
↑1 | https://www.researchgate.net/publication/256479799_Phenotype_of_Normal_Hairline_Maturation |
---|---|
↑2 | https://link.springer.com/article/10.1007/s13555-019-0281-6 |
↑3 | https://www.tandfonline.com/doi/abs/10.1080/14764172.2017.1376094?journalCode=ijcl20 |
↑4 | https://pubmed.ncbi.nlm.nih.gov/31111157/ |